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“Nothing in life is to be feared, it is only to be understood. Now is the time to understand 
more, so that we may fear less.” 
 – Maria Skłodowska Curie 
(7th November 1867 – 4th July 1934) 
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Abstrakti 
 
Perinteiset syöpähoidot eli leikkaushoito, sädehoito, kemoterapia tai näiden 
yhdistelmät, ovat kehittyneet merkittävästi.  Tästä huolimatta hoidon teho voi olla heikko 
tietyissä syöpätyypeissä kuten esimerkiksi mesotelioomassa, keuhkosyövässä tai paksusuolen 
syövässä. Lisäksi hoidon tehoa voi heikentää syövän kehittämä resistenssi käytettyä 
hoitomuotoa vastaan, jolloin saavutettu hoitovaste voidaan menettää. Tämän takia syövän 
uusien hoitomuotojen kehitys tärkeää. Erityisen tärkeää on kehittää hoitoja, joilla on uusi 
toimintamekanismi ja joihin syövän kehittämä hoitoresistenssi muita hoitomuotoja kohtaan ei 
vaikuta. 
Onkolyyttinen virushoito on eräs lupaava syövän hoitomuoto. Ensimmäinen 
länsimaissa hyväksytty onkolyyttinen virus on Imlygic (myös tunnettu nimillä T-Vec ja 
talimogene laherparepvec). Imlygicin hyväksyntä sekä USA:n (FDA) että Euroopan (EMA) 
lääkeviranomaisten toimesta on avannut uusia mahdollisuuksia syöpähoitojen kehittämisessä.  
Yhden hoitomuodon käyttö syövän hoidossa on harvoin tehokasta, erityisesti silloin 
kun kysessä on etäpesäkkeitä muodostava tai pitkälle edennyt tauti. Useiden hoitomuotojen 
yhdistäminen syövän hoidossa on osoittautunut merkittävästi tehokkaammaksi kuin vain 
yhden hoitomuodon käyttö. Tulevaisuudessa konventionaalisten ja uusien hoitomenetelmien 
yhdistäminen saattaa mahdollistaa merkittävästi parempien hoitotulosten saavuttamisen. 
Tässä väitöskirjassa on pyritty osoittaamaan, että yhdistämällä onkolyyttinen 
adenovirus kemoterapian tai biologisen yhdisteen kanssa, voidaan syövän hoitotehoa parantaa 
edellä mainittujen hoitojen yhteisvaikutuksen takia. Väitöskirjassa on kokoeiltu erilaisia 
hoitokombinaatioita, joiden tarkoituksena on ollut parantaa onkolyyttisen virushoidon 
tehokkuutta. Lisäksi väitöskirjassa on tutkittu adenovirusten turvallisuustekijöitä, koska 
geeninsiirron ja virusvektoreiden käytön turvallisuus on yleisesti erittäin tärkeää. 
Väitöskirjassa on tutkittu kemoterapiaan perustuvan käypähoidon (Pemetrexed, 
Cisplatin, Carboplatin) ja onkolyyttisen adenoviruksen Ad5/3-d24-GM-CSF (ONCOS-102) 
yhdistelmähoidon tehoa ihmisen malignin mesoteliooman (MM) malleissa, mitkä olivat 
erilaiset in vitro-mallit että BALB/c-ksenograftimalli. Tutkimuksessa osoitettiin, että hoidon 
teho käytetyissä malleissa parani, kun ONCOS-102 yhdistettiin käypähoidon kanssa 
verrattaessa pelkään virus- tai käypähoitoon. Yhdistelmähoito johti yhteisvaikutukseen, joka 
paransi hoidon tehoa.  
Väitöskirjassa tutkittiin hoitotehoa myös yhdistelmällä, missä dipeptidi L-karnosiinin 
oli kompleksoitu onkolyyttisen adenoviruksen kanssa (virus-L-karnosiinikompleksi). 
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Kompleksin käyttö lisäsi tehoa käytetyissä in vitro- ja in vivo-syöpämalleissa. HCT116 
paksusyöpäsolu- ja A549 keuhkosyöpäsolulinjoissa virus-L-karnosiinikompleksin käyttö 
tehosti viruksen transduktiota sekä lisäsi viruksen infektiivistä tiitteriä verrattuna virukseen 
jota ei oltu kompleksoitu. Virus-L-karnosiinikompleksia tutkittiin kahdessa in vivo-mallissa: 
keuhkosyövän ja paksusuolensyövän ksenograftihiirimalleissa. Kompleksin käyttö johti 
huomattavasti vähentyneeseen kasvaimen kasvuun verrattuna muihin käytettyihin 
hoitoryhmiin. Lisäksi väitöskirjassa tutkittiin kompleksin molekulaarista toimintamekanismia. 
Virusvektoreihin liittyvä turvallisuusarviointi tehtiin käyttämällä eläinkokeita. 
ONCOS-102-viruksen toksisuus- ja biodistribuutiotutkimukset Syyrian hamstereissa ja 
BALB/c-hiirimallissa eivät indikoineet viruksen toistuvan annostelun aiheuttavan 
sivuvaikutuksia. Sivuvaikutuksia arvioinnissa käytettiin eläimen painoa, ruuan kulutusta, 
hematotologiaa, kliinistä kemiaa, histopatologiaa sekä viruksen biodistribuutiota. 
Väitöskirjan tulosten perusteella onkolyyttisen viruksen yhdistäminen 
kemoterapiakäypähoitoon tai viruksen kompleksoiminen L-karnosiinin kanssa johtavat 
syöpähoidon tehoa parantavaan yhdistelmävaikutukseen. Tämä antaa vahvan perusteen tutkia 
yhdistelmien tehoa mesoteliooman sekä keuhko- ja paksusuolensyövän hoidossa potilailla. 
Lisäksi väitöskirjassa esitetyt tulokset viittaavat siihen, että adenovirusta voitaisiin käyttää 
muiden bioaktiivisten lääkkeiden kuljettamiseen kohteeseensa. Tämä olisi avian uusia 
strategia syövän hoidossa. 
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Abstract 
 
Despite major advances in conventional cancer treatments by surgery, chemotherapy, 
radiotherapy and their combination, the outcome remains partially ineffective against 
numerous cancer types, for example mesothelioma, lung cancer, and colon cancer. 
Furthermore, due to resistance factors and the subsequent loss of response, which may occur 
rapidly during the conventional treatments regimes, new anti-cancer agents, presenting new 
mechanisms of action and lacking cross-resistance to commonly used therapies, are in high 
demand. 
Oncolytic virotherapy is a promising anti-cancer strategy, and the approval of the first 
oncolytic virus, Imlygic (T-Vec, talimogene laherparepvec), in Western world by US Food 
and Drug Administration (FDA) and European Medicines Agency (EMA) has opened up new 
perspectives for improved treatment of cancer.  
Single therapy is rarely successful in treating cancer, particularly in metastatic or 
advanced cancer, and survival rates with monotherapies alone are generally poor. The 
combination of multiple therapies to treat cancer has already shown significant results in the 
standard care of cancer. This strategy utilizes the combination of both conventional and novel 
therapies that can bring the future promise of cancer treatment.  
In this thesis it has been hypothesized that by combining oncolytic adenoviruses (oAd) 
with chemotherapeutic drugs and a biological agent we could improve anti-cancer efficacy 
through synergistic effect against cancer. Therefore, we have tested various treatment regimes 
with the overall goal being the improvement of oncolytic virotherapy efficacy. Secondly, 
since safety issues concerning gene therapy and viral vectors are tremendously important, we 
have performed studies on safety issues of adenoviral vectors. In brief, we have evaluated the 
anti-cancer activity of combination treatment with standard of care (SoC) chemotherapy 
(Pemetrexed, Cisplatin, Carboplatin) and Ad5/3-d24-GM-CSF (ONCOS-102) in vitro and in 
a xenograft BALB/c model of human malignant mesothelioma (MM). We could show 
improved anti-tumor effects when ONCOS-102 was combined with SoC chemotherapy 
regimens over chemotherapy and virus alone. Combination therapy resulted in synergistic 
anti-cancer effect improving the therapeutic outcome. In a subsequent study we tested anti-
cancer properties of the dipeptide L-Carnosine complexed with an oncolytic adenovirus 
(virus-L-Carnosine complex). The complex demonstrated improved anti-tumor efficacy both 
in vitro and in vivo in tested cancer models. In HCT116 colon and A549 lung cancer cells, the 
virus-L-Carnosine complex presented a higher transduction level and infectious titer over 
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uncoated oncolytic adenovirus. The in vivo efficacy of the virus-L-Carnosine complex was 
tested in two cancer models: i) lung and ii) colon cancer xenograft mice models. It exhibited a 
significant reduction in tumor growth compared to other tested groups. Additionally, we 
investigated the molecular mechanism underlying the effects of the complex on tumor growth 
reduction. 
Safety assessment of viral vectors was performed in animal studies. Extensive studies 
on toxicity and bio-distribution of ONCOS-102 in Syrian hamsters and experiments in 
BALB/c nude mice indicated no side effects of repeated administration of oncolytic 
adenovirus. The side effects were evaluated by assessment of body weight, food consumption, 
hematology, clinical chemistry, histopathology and bio-distribution.  
We concluded that combinatory studies utilizing oncolytic viruses with standard of 
care chemotherapy and an experimental virus-L-Carnosine complex showed synergistic anti-
cancer efficacy, thus providing a strong rationale for clinical testing of such combinations in 
mesothelioma, lung and colon cancer. Additionally, our studies suggested that adenovirus 
could be used in future studies for delivery of other bioactive drugs as a novel strategy in 
cancer therapy.  
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PART B 
1. REVIEW OF LITERATURE 
1.1 Introduction  
 
Although many kinds of treatment have been developed during the past few decades, 
there is still a lack of effective therapies for advanced cancers. Currently there are no curative 
modalities for malignant mesothelioma (Kondola et al., 2016, Boffetta, 2007), lung cancer 
(Gadgeel et al., 2012) and colon cancer (Sargent, 2015). Although treatments such as surgery, 
chemotherapy and radiotherapy can help to improve patient prognosis and increase patient life 
expectancy, new treatment strategies against cancer are in high demand. Efficient anti-cancer 
agents and their targeted delivery into the tumor mass is a key prerequisite for a successful 
cancer therapy (Jeanbart et al., 2014). Secondly such an approach should be safe and well 
tolerated for cancer patients (Bae and Park, 2011).  
Cancer standard of care is commonly a combination of surgery with chemotherapy 
and/or radiotherapy. However, in advanced cancer patients this approach is inefficient and 
may cause many side effects, including severe complications and even death. Some advanced 
cancer patients are not responding to the standard treatment regime and undergo only 
symptomatic therapy (Pappagallo, 2011) without chances to recover. 
Oncolytic virotherapy is emerging as a potential approach to treat cancer. It takes 
advantage of using viruses, which are specifically engineered to preferentially infect, replicate 
in and kill cancer cells instead of normal cells (Sze et al., 2013, Russell et al., 2012). 
However, this strategy has also disadvantages like low efficacy (Koks et al., 2015), 
production of anti-viral neutralization antibodies (Davis and Fang, 2005) and lack of effective 
antiviral drugs in case of uncontrolled virus replication (Romanowski, 2014).  
Tumors are highly heterogeneous complexes of cells, which develop many 
mechanisms for evading the innate immune response (Marusyk and Polyak, 2010). Therefore, 
efficacy and antitumor responses induced by monotherapy may not be sufficient to eradicate 
cancer cells. Oncolytic viruses exhibit a different mechanism of action from conventional 
anti-cancer approaches (chemotherapy and radiotherapy), giving a possibility for additive or 
synergistic interactions in cancer therapy (Dilley et al., 2005, Siurala et al., 2015). 
Additionally, combined therapies may lead to increased efficacy without additional side 
effects.  
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1.2 Cancer 
 Cancer is still a leading cause of death worldwide, 
with 8,2 millions deaths reported by WHO in 2012. Most of 
the deaths each year are due to lung, stomach, liver, 
colorectal and breast cancer (Ferlay et al., 2015), (Figure 1). 
The global burden of cancer increases constantly because of 
the aging and rapid growth of the world’s population in 
conjunction with an increasing habit of cancer-causing 
behaviors, namely: smoking, physical inactivity and 
‘’westernized’’ diets (Jemal et al., 2011).  
 
 
Figure 1. Cancer statistics. (A) Overview of worldwide cancer statistic, including both 
sexes. Modified from (Cancer-Research-UK, 2015); (B) Age-standardised rate for cancer 
incidence (all cancers excluding non-melanoma skin cancer, both sexes). Modified from 
(Ferlay et al., 2015). 
 
1.2.1 Lung cancer 
Lung cancer derives from abnormal epithelial cells located in the airways of the lungs 
and is the leading cause of deaths worldwide (Figure 1A). There are two major forms of lung 
cancer: i) non–small cell lung cancer (NSCLC), (about 85% of all lung cancers) and ii) small-
cell lung cancer (SCLC, 15%), (Molina et al., 2008). Despite of the improvements in early 
detection methods and the treatment therapies in the last decades, non– small cell lung cancer 
is still often diagnosed at an advanced stage with poor prognosis and no efficient treatment 
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options (Ridge et al., 2013). Therefore, the prevention and treatment of lung cancer is still 
major unmet need. Therapy and diagnostics can be improved by a better understanding of the 
molecular mechanisms of the origin and evolution of this cancer type (Herbst et al., 2008) and 
by developing of more efficient treatment modalities. An age-standardise rate (ASR) of lung 
cancer incidence is presented in Figure 2. NSCLC can be divided into 3 major histologic 
subgroups: i) squamous-cell carcinoma, ii) adenocarcinoma, and iii) large-cell lung cancer. 
Smoking can cause all lung cancer types, however, it is most strongly linked with SCLC and 
squamous-cell carcinoma. Adenocarcinoma is the most common type in patients who have 
never smoked (Herbst et al., 2008).  
 
 
Figure 2. Age-standardised rate for lung cancer incidence (both sexes). Modified from 
(Ferlay et al., 2015). 
 
Epidemiologic studies have shown the tendency of increased lung cancer risk in 
families with lung cancer history. Lung cancer risk and susceptibility is elevated also in rare 
inherited germ-line mutations in p53 (Hwang et al., 2003), retinoblastoma (Herbst et al., 
2008), and other genes (Bailey-Wilson et al., 2004) as well as more common germ-line 
mutation in the epidermal growth factor receptor (EGFR) gene (Bell et al., 2005). More 
recently, an association to single-nucleotide polymorphism (SNP) variation at 15q24–15q25.1 
was demonstrated. The region of the SNP variation covers genes encoding subunits of the 
nicotinic acetylcholine receptor (nAChR) alpha, regulated by nicotine exposure (Hung et al., 
2008, Thorgeirsson et al., 2008, Lam et al., 2007). Lung cancer risk also elevates with 
diminished DNA repair capacity of the cell, resulting from germ-line alterations in nucleotide 
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excision repair genes such as DNA excision repair protein (ERCC1) (Yu et al., 2008). 
Increased expression of DNA synthesis and repair genes in NSCLC, like the regulatory 
subunit of ribonucleotide reductase (RRM1) and ERCC1, correlates with improved treatment 
prognosis (Friboulet et al., 2013, Zheng et al., 2007). 
 
1.2.1.1. Current treatment options for lung cancer 
Surgery, chemotherapy, and radiation or their combinations are used to treat NSCLC 
(Besse et al., 2014). For NSCLC that have not spread beyond the lung area, surgery is 
recommended to remove the cancer tissue. Surgery may also be conducted in combination 
with radiation therapy and chemotherapy in case of advanced cancers where these treatments 
are used prior to surgery to decrease tumors volume and prevent the transmission of cancer 
cells through the blood stream (neoadjuvant therapy). Chemotherapy regimens include 
Cisplatin and Carboplatin based therapies in combination with Paclitaxel (Belani et al., 2005), 
Gemcitabine (Gridelli et al., 2007), Docetaxel (Schiller et al., 2002), Vinorelbine (Tan et al., 
2005), Bevacizumab (Herbst et al., 2007), Erlotinib (Herbst et al., 2005) and Etoposide 
(Rusch et al., 2007, Hanna et al., 2008, Gandara et al., 2003). In some cases, targeted therapy 
(erlotinib (Park et al., 2016), gefitinib (Yang et al., 2016), crizotinib, afatinib (Losanno and 
Gridelli, 2016)) may be used as an alternative to chemotherapy, or after chemotherapy 
treatment.  
Surgery is recommended for cancer patients with stage I or II of NSCLC and provides 
the best curative outcome. Surgery with or without adjuvant chemotherapy for stages IB and 
II is generally recommended. Adjuvant chemotherapy after surgical resection of tumor mass 
provides an increase in survival at 5 years in approximately 5% of the patients. The median 5 
years overall survival (OS) rates range between 45 and 70%. No beneficial treatment effect 
has been observed for adjuvant chemotherapy after an operation for stage I NSCLC. 
However, the benefit of adjuvant chemotherapy increases as the disease progresses (Pignon et 
al., 2008). Stereotactic body radiotherapy (SBRT) may be used in early-stage NSCLC tumors, 
which are smaller than 5 cm and without lymph node involvement (Simone et al., 2013). This 
treatment has become an effective option for inoperable patients with early stage NSCLC. 
Surgery is less frequently used in SCLC, which tends to transmit more quickly than NSCLC 
to other parts of the body. Chemotherapy is the most common treatment option for small cell 
lung cancer as chemotherapeutics circulate throughout the body killing lung cancer cells 
located in different locations. Radiation therapy is used to prevent or treat SCLC that has 
spread into the brain. Radiation therapy is also recommended to prevent tumor recurrence 
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after surgery and for those patients who are inoperative (Fruh et al., 2013, Stahel et al., 2011). 
Cisplatin and Carboplatin based chemotherapy in combination with Etoposide and 
Cyclophosphamide (Tjan-Heijnen et al., 2002) or Doxorubicin, Vincristine, and Methotrexate 
is used in SCLC treatment (Crivellari et al., 2007).  
 
1.3.1. Mesothelioma 
Malignant mesothelioma is an aggressive and a rare form of cancer that develops from 
mesothelium. MM is primarily caused by exposure to asbestos and exhibits a long latency 
period (Belli et al., 2009), usually >30 years. The median survival time for mesothelioma 
patients after diagnosis is typically only 9-12 months (Delgermaa et al., 2011). MM affects 
the pleura (85,5%), peritoneum (13,2%), pericardium (0,5%), and tunica vaginalis (0,8%) 
(Fukuoka, 2014). MM tumors are often poorly responsive to standard therapies and therefore 
incidence is steadily increasing worldwide (Robinson et al., 2005, Delgermaa et al., 2011, 
Szulkin et al., 2014, Gomez and Tsao, 2014, L et al., 2001). The low incidence of MM has for 
a long time limited the discovery of new drugs (Fukuoka, 2014), therefore new treatment 
modalities are highly needed.  
 
1.3.1.1. Current treatment options for mesothelioma 
Currently there are no curative modalities for malignant mesothelioma, however 
treatments such as surgery, chemotherapy and radiotherapy can help to improve patient 
prognosis and increase patient life expectancy (Fennell et al., 2008). Malignant pleural 
mesothelioma (MPM) patients should receive surgical resection (if possible), followed by 
adjuvant radiation therapy and either neoadjuvant or adjuvant chemotherapy (Cisplatin plus 
Pemetrexed for 4 cycles), (Gomez and Tsao, 2014). Several studies have used an intrapleural 
approach in MPM. Intrapleural therapy is meant to increase antitumor efficacy. Most clinical 
studies of intra-cavitary chemotherapy have tested platinum based modalities in conjunction 
with Pemetrexed and Doxorubicin. The median progression free survival (PFS) ranged 
between 7,5 and 13,6 months, while OS ranged from 11,5 to 18,3 months (Chang and 
Sugarbaker, 2004, Lee et al., 2002, Colleoni et al., 1996, Rice et al., 1994, Rusch et al., 1994). 
Hyperthermic intrapleural perfusion chemotherapy with Cisplatin, Pemetrexed and 
Doxorubicin has been studied as well. This approach aims to elevate tumor tissue 
temperatures to 42°C in order to enable chemotherapeutic agents to penetrate the tumor cells 
more efficiently. Clinical studies have shown that this is a feasible treatment strategy and 
have reported the maximum tolerated dose (MTD) of Cisplatin at 225–250 mg/m2 (Rusch et 
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al., 1994, Rice et al., 1994, Lu et al., 2005, Richards et al., 2006, Gomez et al., 2013, Ratto et 
al., 1999).  
 
1.4.1. Colon cancer 
Colon cancer (colorectal cancer, CRC) is the most common type of malignant tumor 
arising from the inner wall of intestine. CRC appears randomly in the sporadic forms (85%) 
and in hereditary familial forms (15%), (Jasperson, 2012). It usually appears as a benign 
from, called a polyp. Early polyp removal prevents their transformation into cancer. 
Colorectal cancer can remain asymptomatic for many years before being diagnosed, since the 
symptoms can vary greatly according to the location of the tumor site. CRC is the third the 
most common tumor in men and the second in women, covering 10% of all tumors worldwide 
with approx. 608 000 CRC related deaths reported each year (approx. 8% of all cancer 
deaths). CRC is the 4th most common cancer cause of death worldwide (Labianca et al., 
2013). In Europe and other western countries, it is the second leading cause of death in both 
males (after lung cancer) and females (after breast cancer), (O'Connell et al., 2004), (Figure 
3). 
 
Figure 3. Age-standardised rate for colon cancer incidence (both sexes). Modified from 
(Ferlay et al., 2015). 
 
1.4.1.1. Current treatment options for colon cancer 
Current treatment of colon cancer depends on the location, size, and stage of the tumor 
as well as the health of the cancer patient. Chemotherapy can extend and refine quality of life, 
however, surgery is still the primary procedure for colon cancer treatment (Labianca et al., 
?? ???
2013, Glimelius et al., 2013) and may be the only form of treatment required. Cancers that 
invade all layers of the bowel wall may continue to invade adjacent organs and local tissues or 
spread throughout the abdomen. Surgery aims at resecting all cancer mass, including adjacent 
organs, such as the uterus, ovaries or bladder. Once the disease has metastasized to lymph 
nodes or to distant organ (liver or the lungs), it is rarely curable by a surgical approach alone 
(Van Cutsem et al., 2014, Jasperson, 2012, Yeatman, 2001, O'Connell et al., 2004). 
Unfortunately, the majority of patients have metastatic, inoperative disease. However patient 
can become eligible for resection after successful chemotherapy (Van Cutsem et al., 2014). 
When the disease has spread to lymph nodes or to distant organ sites, chemotherapy is 
generally recommended in the treatment plan. Adjuvant chemotherapy is usually used for 
patients with nodal disease (Dukes’ stage C). Current modalities utilize 6 months of adjuvant 
chemotherapy with S-phase-specific cytotoxic drugs, including 5-fluorouracil and leucovorin. 
Patients with full-thickness tumors, but without evidence of Dukes’ stage B, seem not to 
respond to chemotherapy. However, immune modulation has been demonstrated to be 
beneficial in these groups of patients. Modulation may take the form of vaccination with 
radiated, autologous tumor cells in combination with the immune adjuvant Bacillus Calmette–
Guerin (BCG), (Yeatman, 2001, Van Cutsem et al., 2014). Systemic chemotherapy includes 
5-fluorouracil, leucovorin, ironotecan, and 5,10-Methylenetetrahydrofolate (Han et al., 2007, 
Gustavsson et al., 2015).  
 
1.5. Adenoviruses 
Adenoviruses (Ads) are non-enveloped DNA viruses of approximately 90 nm in 
diameter. The double-stranded DNA has a length of approximately 36,000 bp and the inverted 
terminal repeats (ITRs) acts as origins of replication (Figure 4). Ads are classified into 57 
human serotypes and 7 different species from A to G.? Their name derives from initial 
isolation from human adenoids in 1953 (Rowe et al., 1953). 
 
?
Figure 4. Schematic representation of human adenovirus genome. Early genes (E1-E4), 
late genes (L1-L5) and ψ replication start point. Modified from (Knipe et al., 2007). 
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Ads are the most intensively studied vectors in gene therapy clinical studies among all 
used viruses (Zamarin and Pesonen, 2015), (Figure 5). Ads have been used as non-replicating 
gene transfer vectors, vaccination vectors (Draper and Heeney, 2010) and as oncolytic cancer 
treatment agents (Zamarin and Pesonen, 2015, Capasso et al., 2015, Ranki et al., 2014a, 
Vassilev et al., 2015). Ads exhibit a natural lytic replication cycle (Alemany et al., 2000), 
their production is efficient, leading to high titer of stable viral particles (Tatsis and Ertl, 
2004), and the Ad genome is easy to modify, allowing genome extension up to 105% of wild 
type’s genome (Hermiston, 2000).  
 
 
Figure 5. Vectors tested in gene therapy clinical trials. Based on database provided by the 
Journal of Gene Medicine (http://www.abedia.com/wiley/vectors.php, 2015). 
 
1.5.1. Adenovirus structure  
Ad consists of 87% protein and 13% DNA (Rux and Burnett, 2004). Studies made by 
electron microscopy (Figure 6) and X ray crystallography showed that icosahedral structure of 
Ad capsid consists of 20 triangular and 12 vertices surfaces. It has 252 capsomere subunits, 
containing 240 hexons and 12 pentons. Each hexon is surrounded by 6 subunits and each 
penton is in direct contact with 5 subunits and has a fiber. Capsid contains three major capsid 
proteins (hexon, penton base and fiber knob) (Zhang and Imperiale, 2003), four minor capsid 
proteins (VI, VIII, IX and IIIa), and four core proteins (terminal protein, protein Mu, VII and 
V), (Nemerow et al., 2009, Rawlins et al., 1984). 
Adenovirus has a linear, double-stranded DNA with a terminal protein (TP) at the 5’ 
ends. The genome consists of 5 early transcription units (E1A, E1B, E2, E3 and E4), three 
delayed early units (IX, IVa2, E2) and one late unit (L1-L5) (Thimmappaya et al., 1982), 
(Figure 4). E1A proteins activate transcription and mediate the entry into the S phase of the 
cell cycle (Knipe and Howley, 2013). Two E1B proteins block apoptosis in adenovirus-
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infected cells. Three E2 proteins mediate DNA replication (Knipe et al., 2007). E3 proteins 
modulate the antiviral host response (Wold et al., 1999). E4 proteins promote adenovirus 
messenger RNA metabolism (Goodrum and Ornelles, 1999), facilitate viral DNA replication 
and inhibit host-cell protein synthesis. Late proteins (L1-L5) are capsid components (Hoeben 
and Uil, 2013).  
  
Figure 6. Electron micrographs of negatively stained viral particles of Ad5F3EGFP. 
Orange arrows indicate the HAdV-3 fiber. Scale bar represents 100 nm (Murakami et al., 
2010). 
 
1.5.2. Adenovirus cell entry  
Adenovirus life cycle consists of two phases: i) the early phase lasting for 5 - 6 hours 
(cell entry) and ii) the second phase starting from the expression of late genes and assembly 
of the virus progeny (replication), (Figure 7). Adenovirus infection starts by the binding of the 
Ad fiber knob to a cell surface receptor. Most adenovirus species (subgroup A, C, E, F) utilize 
the coxsackievirus adenovirus receptor (CAR), (Zhang and Bergelson, 2005, Roelvink, 1999). 
Some Ads bind to CD46 receptor (group B, D), (Zhang and Bergelson, 2005). Ad binding is 
followed by receptor-mediated endocytosis facilitated by interactions between an arginine-
glycine-aspartic acid (RGD) within the adenoviral penton base and cellular αvβ integrins 
(Wickham et al., 1994). Ad counterplays with cells by binding to CAR and moves in random 
motions. Next, Ad engages in acto-myosin-mediated slow drifting motions. Mechanical cues 
on the adenovirus increase from the slow drifts of CAR, and the stalling motions of the 
second virus receptor, integrins. These result in mechanical stress, which initiates the virus-
uncoating program. Ad infection uptake consists of a two-step membrane penetration process. 
The first step is controlled by the mechanical properties of the virus and the cell. The second 
step increases the levels of ceramide in the plasma membrane, and gradually enhances 
?? ???
membrane lesions coincident with virus endocytosis (Greber, 2016). Ad replicates in the 
nucleus. Virus transfers its linear DNA genome, but not the viral capsid, in the nucleus (Wang 
et al., 2013). It uses the molecular motor kinesin-1 to dis-attach its genome from the capsid at 
the cytoplasmic place of the nuclear pore complex (NPC), by docking to the nucleoporin 
Nup214 (Strunze et al., 2011). The kinesin-associated light chain 1,2 attaches to virus capsid 
protein IX, and Nup358 activates the motor domain in the heavy chain. Cascade of these steps 
leads to the disruption of the capsid and a part of nuclear pore complex. The viral DNA is 
imported into the nucleus with involvement of cellular transport factors, such as importins 
and transportins (Flatt and Greber, 2015, Greber, 2016).  
 
 
Figure 7. Adenovirus life cycle (cell and nuclear entry). (Upper panel) Acto-myosin-
mediated drifting motions of Ad attached to CAR and to integrins on the cell surface result in 
disassembly of viral fibers. (Lower panel) Ad (without fibers) binds to the NPC protein 
Nup214 via hexon protein. The microtubule-dependent motor kinesin-1 binds to the protein 
IX by light chain Klc1/2. Motor turns on after heavy chain binding to Nup358 and initiate the 
capsid disruption. Capsid disruption deletes Nup62 from the nuclear pore, and adenoviral 
DNA is transferred into the nucleus. Modified from (Greber, 2016). 
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1.5.3. Adenovirus transcription and replication 
The Ad gene transcription is launched by the production of the viral E1A 
transactivator, leading to a cascade of reactions. Replication is a very efficient process, where 
an infected cell produces approx. one million of viral DNA copies within 40 hours post 
infection. DNA replication begins within the inverted terminal repeats (ITRs) and requires 
three viral proteins encoded by E2 genes: pTP, Ad DNA polymerase and the DNA-binding 
protein (DBP), (Hoeben and Uil, 2013). DNA replication takes place in the nucleus and 
proceeds by a number of steps: i) the release of E2F upon E1A attachment to the Rb tumor 
suppressor, ii) inhibition of the p53 tumor suppressor by E1B- 55K, iii) inhibition of 
apoptosis by the Bcl-2 homologue E1B-19K. The next steps are the inhibition of cellular 
antiviral responses, including reservation of major histocompatibility complex I (MHC I) by 
E3-gp19K, leading to suppression of cytotoxic T lymphocytes (CTLs), and the production of 
specific gene products required for adenoviral DNA replication is activated (Knipe et al., 
2007, Knipe and Howley, 2013). Translation of late genes leads to the production of 
adenoviral capsid proteins. Virions are released by the cell lysis. The genome is packed into 
the assembled capsid. This last step requires disruption of intermediate filaments (vimentin 
and cytokeratin), causing damage of the cell. Released virions can infect surrounding cells 
(Hoeben and Uil, 2013).  
Ads have evolved several mechanisms allowing them to evade from the host immune 
system, such as the production of immune suppressive proteins. E1A neutralizes the immune 
response against the virus by blocking the interferon (IFN) gene activation (Routes et al., 
1996) and hampers the transcription of IL-6 gene and blocks transduction of the IL-6 
signaling pathway (Takeda et al., 1994). Additionally, E1A breaks cell death path induced by 
tumor necrosis factor (TNF, TNF-induced cell death). E1B-19k gene inhibits apoptosis during 
infection (Cuconati et al., 2002, Han et al., 1996, White, 2006). E3 proteins inhibit cellular (T 
cell-mediated) antiviral responses (McSharry et al., 2008, Hoeben and Uil, 2013).  
 
1.6. Oncolytic adenovirus 
Researchers have seen the potential of using viruses in the treatment of cancer from 
the beginning of their discovery, in 20th century. It has been observed that some cancer 
patients acquiring viral infection, like: hepatitis, influenza, measles, smallpox had tumor 
regression (Jessy, 2011). The first use of adenoviruses in cancer therapy was reported in 1956. 
30 cervical carcinoma patients were treated with adenovirus adenoidal-pharyngeal-conjuctival 
virus. 26 out of 40 patients resulted in localized necrosis with mild side effects (vaginal 
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hemorrhage, fever, malaise). However, due to technological limitations, and lack of 
significant findings from clinical trials, studies on virus therapies were discontinued for many 
years (Kelly and Russell, 2007). Nowadays, thanks to advances in genetic engineering, an 
increased understanding of molecular biology, virology, and importantly, an experience in 
pre-clinical and clinical studies with oncolytic viruses in cancer therapies, have gave new life 
to oncolytic virotherapy. The use of new generation tumor-targeted oncolytic viruses has 
emerged as promising approach for novel cancer treatments. 
Oncolytic viruses (OVs) selectively replicate and lyse cancer cells, spreading within 
the tumor mass, circulating into distant metastases, and not significantly harming normal 
cells. OVs can exhibit natural tumor-selective tropism (reovirus), (Kim, 2015) or be 
genetically modified for cancer cell-restricted replication (adenovirus, herpes simplex, 
vaccinia, Newcastle disease virus, measles). OVs are effective at inducing immune responses 
against themselves (anti-viral immune responses), (Pikor et al., 2015) but also to infected 
tumor cells (anti-tumor immune responses), (Lemay et al., 2012, Forbes et al., 2014, Kaufman 
et al., 2015). They can be used as adjuvants and to induce host immune responses against the 
tumor (Capasso et al., 2015). Oncolysis caused by OVs releases tumor epitopes along with 
danger signals like damage-associated molecular pattern (DAMP), OV-derived pathogen-
associated molecular pattern (PAMP) molecules and pro-inflammatory cytokines (Medzhitov 
and Janeway, 2002, Bartlett et al., 2013, Tang et al., 2012). During the oncolysis, tumor 
antigens are collected by antigen presenting cells (APC), processed and presented to naïve T 
cells in lymph nodes. This cascade of reaction leads to the activation of tumor specific T cells, 
which can travel to the tumor and distant metastases and eradicate specific cancer cells. Such 
responses can result in long-lasting anti-tumor memory. OVs trigger also anti-viral immune 
responses, giving the ability of breaking the immunotolerance of tumor microenvironment 
and boosting an induction of anti-cancer effect. Additionally, when arming OV with specific 
co-stimulatory transgenes, it can trigger pro-stimulatory immune response and work as 
immune modulators (Liu et al., 2014, Putzer et al., 2001, Diaconu et al., 2012, Bramante et 
al., 2015).   
Construction of oncolytic viruses in the past has been mainly focused on targeted 
delivery to tumor sites, enhanced replication and more potent lysis. Nowadays more attention 
is given to anti-tumor immunity studies (Seymour and Fisher, 2016, Prestwich et al., 2008). 
OVs serve as a diverse platform for immunotherapy, work as vaccines, and can be armed with 
immunomodulatory transgenes or combined with other anti-cancer therapies. There are two 
clinical approaches with OVs: i) systemic treatment and ii) local immunotherapy (Zamarin 
?? ???
and Pesonen, 2015), (Figure 8). Therefore, OVs are constantly receiving an increasing level 
of attention as anti-cancer agents in clinical studies (Seymour and Fisher, 2016). Many 
clinical studies with OVs are currently ongoing and more results are expected to be published 
in the next couple of years (Pol et al., 2016) 
 
 
Figure 8. Two concepts of using OVs in cancer therapy. (A) Locally administered OV 
produce a strong ‘‘danger signal’’ leading to anti-tumor immune response against cancer 
cells. Additionally oncolytic viruses lyse tumor cells releasing new specific cancer epitopes. 
Immune activation can be improved by immune co-stimulator transgenes coded by the virus. 
Antigen presenting cells pick up tumor antigens and present them to T-cells in the draining 
lymph node. Activated tumor specific CD8+ T-cells recognize and kill cancer cells in both 
injected and non-injected tumor masses. (B) Systemic delivery aims at OVs dissemination 
throughout the body based on either natural or genetically improved tumor tropism. The 
purpose is to deliver/target the OV’s to tumors. Repeated administration of an adenoviral 
vector triggers specific immune reaction against the vector, resulting in neutralization of the 
systemically administered virus by the anti-viral antibodies. Modified from (Zamarin and 
Pesonen, 2015). 
 
1.6.1. ONCOS-102 
ONCOS-102 is a serotype 5, human, double-targeted oncolytic adenovirus with a 
chimeric 5/3 capsid for enhanced cancer cell transduction. It has a 24 bp deletion in the Rb 
binding site of the E1A gene for cancer-cell restricted replication (Koski et al., 2010). 
ONCOS-102 codes for human granulocyte macrophage colony-stimulating factor (GM-CSF) 
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for improved anti-tumor immunity. GM-CSF recruits and activates APC (Dranoff, 2002, van 
de Laar et al., 2012), (Figure 9). ONCOS-102 was engineered using standard cloning 
techniques. A fibre chimeric plasmid was cloned (pAdEasy5/3) and recombined with a shuttle 
vector containing a 24-bp deletion in E1A (pShuttleD24) resulting in pAd5/3-D24. An E3-
shuttle vector pTHSN was created by including a 965-bp deletion into the E3 region to 
incorporate the human GM-CSF gene in place of E3 gp19k and 6.7k. pAd5/3-D24-GM-CSF 
was obtained by homologous recombination in E. coli between pTHSN-GM-CSF and 
pAd5/3-D24. The genome of ONCOS-102 was rescued by digestion and transfection of A549 
cells.  
 
 
Figure 9. Structure of ONCOS-102.?Compared to the wild-type adenovirus serotype 5, it 
has three genetic modifications. The knob of the adenovirus serotype 5 has been changed to 
that of adenovirus serotype 3. Thus, the ONCOS-102 uses adenovirus 3 specific receptors for 
transduction rather that adenovirus 5 specific receptors (CD46, Desmoglein-2, rather than 
CAR).?A Δ24 deletion on the E1A region. The deletion is responsible of the targeting the 
virus replication in the cancer cells. A transgene coding human GM-CSF has been added to 
the E3 region. The human GM-CSF is a cytokine that enhances the immunological response 
towards the tumor, in which the ONCOS-102 is replicating.?
?
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1.6.1.1.  ONCOS-102 mechanism of action 
The mechanism of ONCOS-102 action (Figure 10) has been studied by investigating 
clinical samples (Ranki et al., 2016, Ranki et al., 2014a, Vassilev et al., 2015). Local injection 
of ONCOS-102 in the tumor induces a danger signal, stimulating the production of 
inflammatory cytokines, such as Il-6 and IL-8. ONCOS-102 infects tumor cells and causes 
ICD and releases of tumor antigens, and new virions in the tumor environment. Co-
stimulatory molecule GM-CSF attracts antigen-presenting cells to the tumor. Dendritic cells 
(DCs) take up tumor and virus antigens and migrate to lymph nodes. There antigens are 
presented to naïve T Cells, resulting in T cells activation. Activated T cells identify, attack 
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and eradicate tumor cells expressing specific antigens. ONCOS-102 triggers systemic anti-
tumor T cell responses in cancer patients by direct oncolysis of cancer cells and subsequently 
causing a modulation of tumor microenvironment from Th2 to Th1 type (Ranki et al., 2014b). 
ONCOS-102 sensitizes tumor cells to other immunotherapies by inducing a T-cell positive 
phenotype to an initially T-cell negative tumor mass (Ranki et al., 2014b). Treatment with 
ONCOS-102 has showed a prominent infiltration of TILs to tumors in 11 out of 12 treated 
patients (Ranki et al., 2016). Double mode of action of ONCOS-102 (direct oncolysis and 
induction of anti-tumor immunity) is an important factor, crucial in order to overcome the 
major obstacle with regards to cancer immunotherapy - suppressive tumor microenvironment 
(Diaconu et al., 2012).  
				 	
Figure 10. Mechanism of ONCOS-102 action. Local administration of ONCOS-102 
induces innate and adaptive immune system leading to the development of anti-tumor and 
anti-virus immune responses. Activated T cells recognize, attack and kill tumor cells 
expressing the specific antigens. The effect is systemic (ONCOS-102 replicates in primary 
tumors and metastasis). The mechanism of a triple-action of ONCOS-102: 1) Selective 
replication in tumour cells. ONCOS-102 transduces and replicates in cancer cells, causing 
cancer cell death via lysis. New virions are released, and this process can continue as long as 
tumour cells are available. 2) Activation of immune system and induction of anti-tumour 
response.  GM-CSF is only expressed when the virus replicates, resulting in high local 
concentrations in the tumour (Koski et al., 2010). GM-CSF is among the most potent 
stimulators of APCs, resulting in activation of cytotoxic T-cells against the tumour (Dranoff, 
2003). This process is initially enhanced by the co-stimulatory response provided by 
adenovirus, which per se is a Toll-like receptor agonist and, therefore, a strong activator of 
the innate immune system. The ‘oncolytic cancer’ cell death is an immunologically active 
phenomenon and, in particular, helps create “danger signals” that are useful for anti-tumour 
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immunity (Tuve et al., 2009). Also, lysed tumour cells release tumour antigens for APCs. 
ONCOS-102 is an in situ cancer vaccine for each patient, potentially making it a personalised 
cancer immunotherapy. 3) GM-CSF is a potent recruiter of NK cells. Cancer cells have 
evolved a mechanism to evade immune recognition by inhibiting MHC-I synthesis (Bubeník, 
2004). NK cells do not depend on MHC-1 expression for killing but instead preferentially kill 
MHC-I negative cells such as tumour cells. GM-CSF stimulates increased recruitment of NK 
cells to the tumour site. 
 
1.6.1.2.  ONCOS-102 efficacy – in vitro & in vivo studies 
The efficacy of ONCOS-102 was examined in multiple cancer cell lines. The 
oncolytic potency of ONCOS-102 was as effective as the wild type Ad5 in vitro in MDA-
MB-436 (human breast cancer) and A549 (human lung adenocarcinoma) cells. Effective cell 
killing was seen in human soft tissue sarcoma (STS) lines. Infection with 1 VP/cell resulted in 
more than 50% cell killing in most of the melanoma cell lines tested. In the human cell line 
MDA-MB-436, the combination of ONCOS-102 with cyclophosphamide (CPO) or 4-
hydroperoxycyclophosphamide (4-HP-CP) increased anti-cancer efficacy. The combination of 
1-10 VP/cell of with 4-HP-CP resulted in statistically significant increased cell killing 
compared to virus only or 4-HP-CP alone (Bramante et al., 2016, Siurala et al., 2015, Raki et 
al., 2008). GM-CSF secretion and functionality in vitro were confirmed in A549 and TF1 
(human lymphocyte) cell lines.  
The anti-tumour efficacy of ONCOS-102 and chemotherapy with doxorubicin and 
ifosfamide were studied in an immunocompetent hamster model of STS. ONCOS-102 
(4.5 x 109 VP/kg), doxorubicin (1 mg/kg) and ifosfamide (30 mg/kg) were administered 
separately, simultaneously, or in combination with ONCOS-102 or chemotherapy. The 
treatment with ONCOS-102, doxorubicin and ifosfamide chemotherapy showed synergistic 
anti-tumour effects compared to single agent treatments. Median survival was significantly 
longer (p=0.001 or 0.002) in the delayed chemotherapy group (50 days), the simultaneous 
chemotherapy group (27 days), and the delayed ONCOS-102 group (27 days) than in the 
mock group (19 days). No major toxic changes were seen in any group. The data support the 
use of ONCOS-102 in combination with doxorubicin and ifosfamide for the treatment of STS 
(Siurala et al., 2015). ONCOS-102 (4.5 x 1011 VP/kg) displayed effective anti-tumour activity 
in a human melanoma xenograft NMRI nude mouse model. Complete tumour regression was 
observed in the group that received ONCOS-102 in combination with low-dose CPO, and 
near-complete tumour regression was observed in the group that received ONCOS-102 alone. 
Thus, ONCOS-102 is a promising treatment of melanoma. 
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1.6.1.3.  ONCOS-102 – clinical study 
ONCOS C1 (NCT01598129) was an exploratory, open label study of ONCOS-102 
given in combination with low dose CPO in patients with refractory injectable solid tumours. 
Twelve patients (5 male, 7 female; aged 38 to 68 years [median age 63 years]) were treated 
with ONCOS-102: 3 patients were treated with 3 x 1010 VP/injection, 3 patients with 
1 x 1011 VP/injection, and 6 patients with 3 x 1011 VP/injection. Dosing was scheduled on 
Days 1, 4, 8, 15, 29, 57, 85, 113, and 141. Five patients received the maximum of 9 doses of 
ONCOS-102, and 3 patients completed the study as planned. Patients also took oral CPO 
50 mg daily throughout the treatment. The underlying cancer types differed widely across the 
study population with 9 different cancer types reported in 12 patients. Post baseline Response 
Evaluation Criteria In Solid Tumors (RECIST) evaluations were available for 10 patients. Of 
these, 4 patients (40.0%) had disease control (stable disease) at 3 months while all of the 
patients had progressed at 6 months. Responses according to immunologically relevant 
RECIST were consistent with the responses according to RECIST. Post baseline positron 
emission tomography (PET) response data were available for 10 patients. Of these, 4 patients 
(40.0%) had disease control. At 3 months, 1 patient had a minor metabolic response, and 
2 patients had stable metabolic disease based on modified PET response. There were 
5 patients with PET response data after 6 months. Of these, 1 patient had stable metabolic 
disease; the remaining 4 patients had progressive metabolic disease. Median progression-free 
survival was 2.9 months. Median overall survival was 9.3 months in the per protocol 
population (n=10). Exploratory immunohistochemistry analysis of tumour biopsies showed 
infiltration of immune cells (CD3, CD4, CD8, CD25, CD11c, CD19, CD68, CD163) into the 
tumour site 1 month after treatment initiation. On Day 57, CD8 cells were increased further 
whereas the corresponding ratio of the other immune cells was lower on Day 57 than on 
Day 29, and was <1 (i.e. below baseline values) for CD3, CD4, CD11, CD19, and CD68 
cells. Viral genomes were detected in blood after every injection of ONCOS-102, with peak 
values occurring at 6 hours after injection. Neutralising antibody titres increased between 
baseline, Day 15 and did not return to pre-dose values in any patient. Blood samples for 
analysis of peripheral blood mononuclear cells (PBMCs) were evaluable for 10 out of 
12 patients. Analysis of PBMCs was possible 2 patients, in whom ONCOS-102 induced a 
systemic anti-tumour CD8+ T-cell response. In both cases, this immune response correlated 
with a clinical response.  
ONCOS-102 was well tolerated. No dose limiting toxicities (DLTs) and MTD were 
identified. There was no relationship between the dose of ONCOS-102 and the intensity of 
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adverse events. The most common adverse event was pyrexia. Other common adverse events, 
reported in few patients were chills, fatigue, injection site pain, feeling cold, decreased 
appetite, nausea (Grade 1 or Grade 2). Grade 3 adverse events were reported in 6 patients 
(pyrexia, increased alkaline phosphatase, increased aspartate aminotransferase [AST], 
proteinuria, hyponatraemia, anaemia, fatigue). Grade 4 adverse events were not reported 
(Ranki et al., 2016, Ranki et al., 2014a, Vassilev et al., 2015).  		
1.6.2. Combination of oncolytic viruses with other anti-cancer therapies 
 Tumors are highly heterogeneous mixture of cells, containing stroma cells, cancer 
cells, and immune cells, which stimulate tumor progression and maintain an 
immunosuppressive environment (Devaud et al., 2013). Tumor develops many mechanisms 
for evading the innate and adaptive immune response. Some tumor infiltrating immune cells 
have the ability to negatively regulate immune responses against the tumors due to the 
presence of regulatory T cells (Tregs), myeloid suppressor cells (MDSC), and type 2 
macrophages (M2). Additionally, tumors themselves can promote suppression of antitumor 
immunity by exhibition of the NKG2D and MICA/B ligands which inhibit the functionality of 
natural killer cells (NK), T cell function (Groh et al., 2002) and accelerate the production of 
immunosuppressive CD4+ T cells (Groh et al., 2006). Soluble immune-suppressors (IL-10, 
histamine, hydrogen peroxidase, adenosine) produced by tumor cells can also block cytotoxic 
T lymphocytes (Palazon et al., 2012). Therefore, efficacy and antitumor responses induced by 
one treatment modality may not be sufficient to eradicate cancer cells.  
Oncolytic viruses exhibit different anti-cancer mechanism compared to conventional 
therapies (chemotherapy, radiotherapy), allowing the possibility for additive or synergistic 
effect in cancer therapy. Additionally, combined therapies may lead to increased efficacy 
without additional side effects. Finally, since antitumor immune responses triggered by 
oncolytic adenoviruses may not be sufficient to eradicate tumors, additional treatment 
combinations are needed (Nguyen et al., 2014). 
 
1.6.2.1. Chemotherapy combination 
 Combining oncolytic viruses with chemotherapeutics can accelerate stronger cytotoxic 
responses (Ottolino-Perry et al., 2010) and potentiate oncolysis. Chemotherapy can enhance 
the replication of oncolytic viruses and weaken the immunosuppressive tumor 
microenvironment (Nguyen et al., 2014). A clinically highly relevant strategy is therefore the 
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use of oncolytic viruses as adjuvants to standard chemotherapy, since most of the cancer 
patient have been or will be exposed to chemotherapy. Table 1 presents combined therapies, 
which have resulted in synergistic anti-cancer responses.  
 
Table 1. Chemotherapy and oncolytic viruses combinations – mechanism of synergy. 
Based on (Tusell Wennier et al., 2012). 
Oncolytic virus Chemotherapy Mechanism of synergy 
Herpesviruses, Reovirus, 
Adenoviruses, Poxviruses, 
Paramyxoviruses 
Cyclophosphamide Suppression of the host’s innate and adaptive anti-viral immune responses. Enhanced viral replication 
Herpesviruses Cisplatin Improves viral replication by up-regulation of GADD34 
Adenoviruses Gemcitabine E1A expression prevents drug resistance 
Adenoviruses, Herpesviruses 5-FU Up-regulation of CAR expression level 
Adenoviruses, Herpesviruses Taxenes Virus replication is elevated in drug resistant cells (an up-regulated Raf/MEK/ERK molecular pathways) 
Rhabdoviruses, 
Herpesviruses, Poxviruses, 
Adenoviruses 
Histone deacetylase 
inhibitors 
Reduction of IFN production in infected cancer cells 
results in enhanced viral replication. Up-regulation of 
CAR expression level 
Rhabdoviruses, Poxviruses, 
Poxviruses, Adenoviruses Rapamycin 
Inhibited IFN production in infected cancer cells, 
increased viral replication 
Poxviruses Cyclooxygenase 2 Inhibited anti-viral antibody production, enhanced viral replication 
  
Many preclinical studies have proven that combination therapy using OVs and 
chemotherapy may enhance therapeutic outcome (Siurala et al., 2015, Pandha et al., 2009, Lin 
et al., 2008). Indeed, China has approved the first oncolytic virus H101 (Oncorine) for the 
treatment of head and neck cancer. Phase III clinical studies showed a better response for 
H101 in combination with Fluorouracyl (5-FU), (72%) over chemotherapy alone (40%), 
(Garber, 2006). 
 Current cancer treatments are mainly based on chemotherapeutic agents. Most of these 
cytotoxic drugs work by inhibiting DNA replication or by disrupting microtubule structures. 
Cyclophosphamide (CPA) can increase the amount of OVs needed to obtain a therapeutic 
benefit in cancer therapy (Kambara et al., 2005). CPA inhibits DNA replication and activates 
cell death. The synergistic mechanism in immunotherapy is most likely related to the CPA’s 
effect on host immune system, rather than enhancement of viral replication in cancer tissue. 
CPA exhibits immunosuppression activities leading to reduction of OV related toxicities. 
CPA also depletes Treg cells responsible for tumor-induced immune tolerance. Thus, the 
treatment with cyclophosphamide can sensitize cancer cells to immunotherapy (Ghiringhelli 
et al., 2004). Finally, OVs promote anti-cancer responses, which can be further enhanced by 
CPA-mediated depletion of Treg cells. Improved cancer treatment efficacy has been shown 
with HSV-2 and reovirus in combination with CPA (Kottke et al., 2009, Cerullo et al., 2011). 
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Cisplatin is a platinum based chemotherapeutic drug, acting by crosslinking of DNA 
and causing apoptosis in the cell. In animal studies with murine melanoma (B16F10), a 
synergistic anti-cancer effect has been shown when combined with reovirus. Combined 
therapy inhibited the OV-stimulated cytokine and chemokine assembly, however, with no 
impact on humoral immune responses (Pandha et al., 2009). Cisplatin has improved oncolysis 
of Herpes simplex virus type 1 (HSV-1) in NSCLC (Toyoizumi et al., 1999). Additionally, 
combination of Cisplatin with adenovirus facilitated the replication of the virus and 
significantly reduced the tumor progression (Cheong et al., 2008). Synergistic effects have 
been also reported in a MPM with NV1066 (HSV-1 based virus), (Adusumilli et al., 2006).  
 
1.6.2.2. Radiotherapy combination 
 There is an increasing interest in combining oncolytic viruses with radiation therapy, 
as the mechanism of theses therapies is systematically better understood. It is already known 
that radiation-enhancement of oncolysis or viruses-caused sensitization of the cancer tissue to 
radiotherapy has led in synergistic anti-cancer effect in many animal studies (Ottolino-Perry 
et al., 2010). Combination therapy using Ad2/5 (Geoerger et al., 2003), Ad-delta24 (Idema et 
al., 2007), Ad-delta24-p53 (Idema et al., 2007), and Ad-delta24-RGD (Ottolino-Perry et al., 
2010) with external beam radiotherapy (XRT) in a glioma cancer model led to an increase of 
50%-100% in long-term survival. Furthermore, synergistic antitumor effect has been 
observed when combining adenovirus CV706 with XRT in prostate cancer xenograft model 
from 7 to 42 days after the treatment, resulting in significant tumor mass reduction and 
complete response (CR) in 80% of mice. Additionally, XRT combined with CV706 has 
reduced in serum prostate specific markers compared to monotherapy. 
 Viral replication is enhanced in the to presence of XRT. It was hypothesized that 
radiation promotes an increase in cellular GADD34 expression levels, which correlates with 
replication ratio. This protein protects cells against genetic disruption, including those caused 
by radiation. Furthermore, XRT enhances the uptake of adenoviruses due to up-regulated 
expression of coxsackie adenovirus receptor (CAR) and integrin (Ottolino-Perry et al., 2010). 
 
1.6.2.3. Combination with other therapeutic agents 
 One of the most promising therapeutic approaches in cancer therapy are combination 
of OVs with immune checkpoint inhibitors. Since it’s known that i) inhibition of immune 
checkpoints is a crucial for efficient immunotherapy and ii) immune responses stimulated by 
oncolytic viruses exhibit the antitumor effect, this combination can lead to potent clinical 
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benefits (Rojas et al., 2015), (Figure 8). There is limited preclinical data supporting this 
approach, however promising clinical data has been registered, such as T-Vec combined with 
ipilimumab and pembrolizumab. T-Vec in combination with ipilimumab in advanced 
melanoma patients achieved in an overall response rate (RR) of 50% and a tolerable safety 
profile. Patients treated with pembrolizumab, 9 out of 16 showed 56.3% response rate with 
the diseases control rate being 68.8% (reported at 2015 European Cancer Congress). 
Adenoviruses, thanks to their efficient cell-entry mechanism, low pathogenicity for 
humans and well-known biology, are among the most popular delivery vectors in gene 
therapy (Crystal, 2014). They are commonly used as vaccine vectors as they induce innate 
and adaptive immune responses (Volpers and Kochanek, 2004). It has been shown that by 
attaching tumor-specific MHC-I-restricted peptides onto the adenoviral surface (virus works 
as a vector/adjuvant), it is possible to target immunity towards the tumor, causing a 
significantly increased anti-cancer efficacy in melanoma (Capasso et al., 2015). 
 
1.7. Anti-cancer effect of L-Carnosine  
Carnosine is a natural dipeptide (β-alanyl-L-histidine), (Figure 11), synthesized by 
Carnosine synthetase. Dipeptide is highly concentrated in muscle, brain tissues, and also 
present in lungs, kidney, and stomach (Iovine et al., 2012). Since the discovery of Carnosine 
in 1900, many efforts have been made to determine its biological properties (Gaunitz and 
Hipkiss, 2012). Some physiological functions have been described, like antioxidant 
(Babizhayev, 1989, Lee and Hendricks, 1997), anti-inflammatory (Lee et al., 2015), anti-
senescence (Wang, 2000), and anti-cancer activity (Iovine et al., 2014). 
 
Figure 11. Structure of L-Carnosine. L-Carosine is a strong antioxidant that cleans oxygen 
free radicals and chelates heavy metals. It inhibits protein-protein and protein-DNA cross-
links induced by hypochlorite anions and toxic aldehydes. Modified from (Boldyrev et al., 
2013). 
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Nagai and Suda first reported anti-cancer function of Carnosine in 1986. In their 
experiment sarcoma-180 cells were implanted into ddYY mice, followed by the treatment 
with Carnosine (50mg/kg/day) every two days. Dipeptide significantly inhibited tumor 
progression and increased survival (Gaunitz and Hipkiss, 2012). Renner et al. reported that 
Carnosine reduced the proliferation of tumor cells obtained from human glioblastoma (Renner 
et al., 2007) by inhibiting the glycolytic energy metabolism crucial for cancer cells (Renner et 
al., 2010). The effects of Carnosine were also investigated in human gastric carcinoma cells. 
The study demonstrated that Carnosine reduced the proliferation of tumor cells by retarding 
Akt/mTOR/p70S6K signaling (Zhang et al., 2014). Other experiment has shown an ability of 
Carnosine to inhibit the growth of human HCT116 colon cancer cells. Carnosine (50-100 
mM) decreased concentration of adenosine triphosphate (ATP) and reactive oxygen 
species (ROS), and arrested cell cycle in G1 phase.  Findings presented by Iovine et al. 
supported the hypothesis that Carnosine could reduce HCT116 cell growth via its antioxidant 
properties, and its ability to affect glycolysis (Iovine et al., 2012). Additionally, the dipeptide 
might be considered as a potential agent for the treatment of metastatic SK-Hep-1 cells by 
inhibition of matrix metaoproteinase-9 expression and induction of an anti-metastatic gene, 
nm23-H1 (Chuang and Hu, 2008).  	
1.8. Clinical trials with oncolytic viruses 
There has been interest in using of oncolytic viruses in cancer treatment for over 
decades.  Previous clinical efforts have concentrated on the safety of oncolytic viruses. 
However, this trend is nowadays switching to studies focused on treatment efficacy. Today 
clinical data is available from six, the most well studied oncolytic viruses: adenovirus, 
reovirus, measles virus, herpes simplex virus (HSV), Newcastle disease virus and vaccinia 
virus. Generally speaking, these viruses have been safe and well tolerated in clinical setting 
(Aghi and Martuza, 2005, Pol et al., 2014, Patel and Kratzke, 2013).  
OVs went through several peaks and falls of scientific activity and interests during the 
last century (Kelly and Russell, 2007). Jesse Gelsinger’s death after the treatment with non-
replicating adenovirus, affected the development of OV gene therapy too (Thomas et al., 
2003). However, nowadays the interest in OVs appears to be remarkably increasing. Further 
evidence of clinical efficacy is still pending, as randomized clinical studies are ongoing. 
However, the recent approval of T-Vec by EMA and FDA gave additional attention and 
interest to virotherapy. T-Vec (Harrington et al., 2015) is the first oncolytic vector approved 
in Western countries and second in the world after Oncorine, (Liang, 2012), (approved by 
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China's State Food and Drug Administration SFDA in 2005). T-Vec is a genetically modified 
herpes simplex virus type 1 coding for GM-CSF. Neurovirulence factors ICP34.5 and ICP4 
have been removed for selective virus replication and increased immunogenicity (Zamarin 
and Pesonen, 2015).  Clinical efficacy of this virus in advanced melanoma has been 
demonstrated in Phase II and III of clinical trials (Kohlhapp and Kaufman, 2015). 
Furthermore, clinical efficacy has been demonstrated in cancer patients with pancreatic, 
breast and colorectal cancers (Hu et al., 2006). Oncorine is a genetically modified type 5, 
adenovirus, engineered by Shanghai Sunway Biotech. It obtained regulatory approval for the 
treatment of head and neck cancer. H101 has been constructed to remove a segment of E1B-
55KD responsible for the interaction with a normal human gene p53, which is normally 
deregulated in many cancers (Garber, 2006).  
Over the past years, dozens of oncolytic viruses have been tested in clinical trials with 
studies mainly concentrated on six viral species listed and introduced in Tables 2-3.  
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T
able 2. C
linical trials w
ith oncolytic viruses. 
V
irus 
V
ector’s 
nam
e 
Phase 
Indication 
R
oute 
C
linical outcom
e 
R
eference 
A
denovirus 
O
N
C
O
S-
102* 
I/II 
M
alignant Solid Tum
ors 
i.t. 
- N
o D
LT or M
TD
 w
as identified for O
N
C
O
S-102. 
- 4 out of 10 patients had disease control based on PET/C
T 
scan at 3 m
onths. 
- M
edian overall survival w
as 9.3 m
onths. 
- H
igh infiltration of TILs to tum
ors in 11 out of 12 patients. 
- H
igh expression levels of genes associated w
ith activated 
T
H 1 type im
m
une profile w
ere detected. 
- Treatm
ent w
ith O
N
C
O
S-102 resulted in infiltration of C
D
8+ 
T cells to tum
ors and up-regulation of PD
-L1. 
(V
assilev et 
al., 2015, 
R
anki et al., 
2014a, R
anki 
et al., 2016) 
O
nyx-015*, 
# (dl1520) 
I-III 
Lip and O
ral C
avity C
ancer 
H
ead and N
eck C
ancer 
O
ropharyngeal C
ancer 
i.v. or 
i.t. or 
i.p. or 
hepatic 
arterial 
- O
ver 200 cancer patients have been treated. 
- The virus w
as generally w
ell tolerated at doses of up to 
2 x 10
12 V
P. 
- N
o M
TD
 w
as identified by any route of adm
inistration. 
- V
iral replication w
as tum
or-restricted. 
- A
nti-cancer efficacy w
as show
n w
hen com
bining O
nyx-015 
w
ith chem
otherapy regim
e. 
(K
irn, 2001b, 
H
abib et al., 
2001) 
H
101* 
I-III 
M
alignant H
ydrothorax 
N
on Sm
all C
ell Lung C
ancer 
M
elanom
a 
B
rest cancer 
O
varian cancer 
G
astric carcinom
a 
R
ectal cancer 
thoraci
c cavity 
perfusi
on 
- N
o D
LT and serious adverse events w
ere not observed. 
- R
em
arkable anti-cancer effect in 3 out of 15 patients (1 
partial response [PR
], 2 m
inor responses [M
R
s], Phase I). 
- C
R
 w
as obtained in 3 patients, PR
 in 11, and objective 
response rate (O
R
R
) w
as 30.4%
 (14/46, Phase II). 
- 
Enhanced 
anti-cancer 
efficacy 
w
as 
observed 
w
hen 
com
bining H
101 and chem
otherapy. 
- O
R
R
 from
 com
bining H
101 w
ith chem
otherapy w
as higher 
than in chem
otherapy cohort alone (79%
 vs. 39.6%
, Phase 
III). 
(Liang, 2012, 
Y
u and Fang, 
2007) 
IC
O
V
IR
-7 
I/II 
A
dvanced and refractory solid 
tum
ors 
i.t. 
- The treatm
ent w
as w
ell tolerated w
ith m
ild to m
oderate side 
effects. 
- O
R
R
 w
as seen in 9 of 17 patients. 
- 5 of 12 patients had stabilization or reduction in tum
or size 
(1 PR
 and 2 M
R
s). 
(N
okisalm
i et 
al., 2010) 
K
H
901 
I 
H
ead and N
eck 
i.t. 
- The treatm
ent w
as w
ell tolerated, w
ith the m
ain toxicity 
being grade 1/2. 
- Intratum
oral adm
inistration of K
H
901 w
as associated w
ith 
biological activity, how
ever further investigation of K
H
90 is 
needed. 
 
(C
hang et al., 
2014) 
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O
B
P-301 
I/II 
C
arcinom
a, H
epatocellular 
i.t. 
- The treatm
ent w
ith O
B
P-301 w
as w
ell tolerated. 
- N
o D
LT w
as detected after a single intratum
oral injection of 
O
B
P-301. 
- A
ll patients had stable disease at the day 28. 
- 6 patients show
ed 6.6 to 34%
 tum
or size reduction. 
(Sakai et al., 
2010, Y
ano et 
al., 2015) 
C
oloA
d1** 
I/II 
R
esectable C
olon C
ancer, 
R
esectable N
on-sm
all C
ell Lung 
C
ancer, R
esectable B
ladder 
C
ancer, R
esectable R
enal C
ell 
C
arcinom
a 
i.t. or 
i.v. or 
i.p. 
-  no clinical data 
(D
i et al., 
2014, B
auzon 
et al., 2009) 
A
d5-
C
D
/TK
rep  
I 
Prostate 
i.t. 
- N
o D
LT and the M
TD
 w
as not defined. 
-  94%
 of the adverse events observed w
ere m
ild or m
oderate. 
- 7 of 16 (44%
) patients dem
onstrated a ≥25%
 decrease in 
serum
 prostate-specific antigen (PSA
), and 3 of 16 (19%
) 
patients dem
onstrated a ≥50%
 decrease in serum
 PSA
. 
(Thom
pson 
and 
R
odriguez, 
2007, Freytag 
et al., 2003) 
C
G
0070 
I-III 
C
arcinom
a, Transitional C
ell, 
B
ladder C
ancer 
i.v. 
- G
rade 1–2 bladder toxicities w
ere the m
ost typical adverse 
events. 
- D
LT w
as not reached. 
- The C
R
 rate w
as 48.6%
. 
- In the m
ultidose cohorts the C
R
 rate for the com
bined groups 
w
as 63.6%
 (14 of 22 patients). 
- In exploratory patients w
ho received the m
ultidose schedules 
had an 81.8%
 C
R
 rate (9 of 11patients). 
(B
urke et al., 
2012, R
am
esh 
et al., 2006) 
D
N
X
2401 
(D
elta-24-
R
G
D
-4C
) 
I 
B
rain C
ancer, C
entral N
ervous 
System
 D
iseases, G
lioblastom
a or 
G
liosarcom
a 
i.t. 
- D
LT w
as not reached. 
- 
A
nti-cancer 
efficacy: 
12%
 
of 
the 
patients 
had 
C
R
 
(rem
arkable com
plete response). 
- A
n overall m
edian survival w
as 11 m
onths. 
(Lang et al., 
2014) 
              
 
 
T-V
ec 
(O
ncoV
EX
)
** 
 
I-III 
 M
elanom
a 
 
 i.t. 
- Tolerable side-effect profile. 
- The only grade 3 or 4 adverse events occurred in ≥ 2%
 of 
treated patients. N
o fatal treatm
ent-related A
Es occurred. 
 - Enhanced durable response rate and a trend tow
ard superior 
overall survival.   
- T-V
EC
 is currently being evaluated in com
bination w
ith 
other im
m
une therapies (ipilim
um
ab and pem
brolizum
ab). 
(A
ndtbacka et 
al., 2015, 
H
arrington et 
al., 2015, 
Johnson et al., 
2015) 
G
207 
I-II 
Supratentorial N
eoplasm
s, 
M
alignant, 
G
liom
a, A
strocytom
a, 
G
lioblastom
a 
H
ead and N
eck C
ancer 
i.t. 
 - The treatm
ent w
as w
ell tolerated. 
- The m
edian survival tim
e of G
207 inoculation w
as 7.5 
m
onths.  
- The study show
ed potential anti-cancer effect of single-dose 
of G
207 w
ith radiation in the treatm
ent of m
alignant gliom
a 
patients.  
 (M
arkert et al., 
2014, A
ghi 
and C
hiocca, 
2009) 
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H
erpes 
sim
plex virus 
- A
dditional studies w
ith G
207 in the treatm
ent of hum
an 
gliom
a are recom
m
ended. 
- G
207 could be considered for the treatm
ent of head and neck 
cancer. 
1716 (H
SV
-
1716)* 
I-II 
M
alignant Pleural M
esotheliom
a,	
R
habdom
yosarcom
a,  
O
steosarcom
a,   Ew
ing Sarcom
a,   
Soft Tissue Sarcom
a,  
N
euroblastom
a,   W
ilm
s Tum
or,   
M
alignant Peripheral N
erve 
Sheath Tum
or,   C
lival 
C
hordom
a,  N
on-C
N
S Solid 
Tum
ors, R
ecurrent C
hildhood 
A
naplastic A
strocytom
a, 
R
ecurrent C
hildhood A
naplastic 
O
ligoastrocytom
a, 
R
ecurrent C
hildhood G
liosarcom
a 
i.t. 
- N
o D
LT w
as observed 
- Three patients rem
ain alive and clinically stable at 15, 18 
and 22 m
onths post-surgery and H
SV
-1716 injection.  
- M
icroscopic evidence of tum
or necrosis after H
SV
-1716 
injection (3 patients). 
  
(Toyoizum
i et 
al., 1999, 
M
ace et al., 
2008, D
anos, 
2008, M
acK
ie 
et al., 2001) 
H
F10** 
I-II 
R
efractory H
ead and N
eck 
C
ancer,  Squam
ous C
ell 
C
arcinom
a, Skin, M
alignant 
M
elanom
a, Solid Tum
or 
i.t. 
- The treatm
ent w
as w
ell tolerated. 
- 30-100%
 of histopathological regression in recurrent breast 
cancer.  
- SD
 in 3 patients, PR
 in 1 patient and progression disease 
(PD
) in 2 patients. 
(K
apural et al., 
2015, Tan et 
al., 2015, Luo 
et al., 2012, 
N
akao et al., 
2011) 
M
easles virus 
(M
V
) 
M
V
-C
EA
 
I 
 A
dult A
naplastic A
strocytom
a, 
A
dult A
naplastic 
O
ligodendrogliom
a, 
A
dult G
iant C
ell G
lioblastom
a, 
A
dult G
lioblastom
a, 
A
dult M
ixed G
liom
a, 
i.p. 
- N
o clinical or biochem
ical evidence of toxicity. 
- 
Safety 
of 
C
N
S 
adm
inistration 
of 
M
V
-C
EA
 
in 
gliom
a 
patients. 
- M
edian follow
 up, 11 m
onths. 
(G
alanis et al., 
2010, Zhang 
et al., 2012, 
M
yers et al., 
2006) 
N
ew
castle 
disease virus 
(N
C
D
) 
PV
701* 
I 
 R
ecurrent Salivary G
land C
ancer, 
R
ecurrent Squam
ous C
ell 
C
arcinom
a of the H
ypopharynx, 
R
ecurrent Squam
ous C
ell 
C
arcinom
a of the Larynx, 
R
ecurrent Squam
ous C
ell 
C
arcinom
a of the Lip and O
ral  
C
avity, 
R
ecurrent Squam
ous C
ell 
C
arcinom
a of the N
asopharynx, 
i.v. 
 - N
o D
LT w
as observed. 
- M
ild flu-like sym
ptom
s w
ere com
m
on follow
ing the first 
infusion. 
- Tum
or regression w
as observed in a patient w
ith anal 
carcinom
a follow
ing palliative radiotherapy. 
- O
R
R
 occurred at higher dose levels, and PFS ranged from
 4 
to 31 m
onths. 
  (Pecora, 2002, 
Prince et al., 
2005, Lorence 
et al., 2007, 
H
otte et al., 
2007) 
		
42	
R
ecurrent Squam
ous C
ell 
C
arcinom
a of the O
ropharynx, 
R
ecurrent Squam
ous C
ell 
C
arcinom
a of the Paranasal Sinus 
and N
asal C
avity, 
Salivary G
land Squam
ous C
ell 
C
arcinom
a, 
R
eovirus 
R
EO
LY
SIN
*,** 
I-II 
Pancreatic A
denocarcinom
a, 
K
R
A
S M
utant M
etastatic 
C
olorectal C
ancer, C
arcinom
a, 
Squam
ous C
ell of the H
ead and 
N
eck, M
etastatic B
reast C
ancer, 
M
etastatic Pancreatic 
A
denocarcinom
a, C
arcinom
a, 
Squam
ous C
ell of the H
ead and 
N
eck 
i.v. or 
i.t. 
- Treatm
ent w
as tolerable and m
ore effective com
pared to a 
single agent gem
citabine. 
- U
p-regulation of im
m
une checkpoint m
arker PD
-L1. 
- 8 of 13 patients in the study had SD
 for 12 w
eeks or longer, 
(C
R
 + PR
 + SD
 of 62%
). 
(Sborov et al., 
2014, 
M
ahalingam
 
et al., 2015b, 
A
rnberg, 
2012, 
V
illalona-
C
alero et al., 
2015, 
M
ahalingam
 
et al., 2015a) 
 
V
accinia 
virus (V
V
) 
 
JX
-594* 
 
I-II 
C
olorectal cancer, M
elanom
a, 
Lung C
ancer, O
varian C
ancer, 
Soft-tissue Sarcom
a, B
rest 
C
ancer, N
eoplasm
a, Liver, 
C
arcinom
a 
 
i.t. 
- The treatm
ent w
as w
ell tolerated. 
- A
nti-tum
or efficacy in 3 patients. 
- 
O
bjective 
intrahepatic 
M
odified 
R
esponse 
Evaluation 
C
riteria 
in 
Solid 
Tum
ors 
(m
R
EC
IST) 
w
as 
15%
 
and 
intrahepatic disease control w
as 50%
. 
- M
edian survival of 14.1 m
onths. 
(Park et al., 
2015, Parato 
et al., 2012, 
W
alther and 
Stein, 2015, 
Liu et al., 
2008, H
eo et 
al., 2013) 
*   alone or in com
bination w
ith chem
otherapy 
** alone or in com
bination w
ith im
m
une checkpoint blockade 
#   alone or in com
bination w
ith radiation 
   
		 43	
Table 3. Overview of the oncolytic viruses used in clinical trials. 
Virus Nucleic acid Characteristic 
Adenovirus 
DNA 
• Non-enveloped, lytic double-stranded DNA virus 
• Genome of approx. 36kbp 
• Adenoviruses are classified into 57 human serotypes and into 7 different 
groups from A to G 
• Common cold-causing virus 
• Immunogenic 
• The most well studied vector in clinical studies among others (vaccination, 
oncolytic cancer agent, non-replicating gene transfer vector), (Zamarin and 
Pesonen, 2015, Draper and Heeney, 2010, Jiang et al., 2015) 
Herpes 
• Lytic, double-stranded enveloped DNA Herpes simplex virus type 1 
• Large genome (152kbp), nonessential genes can be replaced up to 30kbp 
• Can establish latency 
• Neurovirulence tropism 
Vaccinia 
• Enveloped double-stranded DNA virus 
• Genome of 200kbp, allowing insertion of a large transgenes without loss of 
infectivity 
• Replicates within the cytoplasm of host cell 
• Highly lytic 
• Highly immunogenic 
• High efficiency of infection 
• Wild type does not infect tumor cells, however the tropism can be redirected 
Measles 
RNA 
• Negative-stranded enveloped RNA virus 
• Genome of approx. 16kbp 
• Causing highly contagious measles disease. MV infections are mostly 
eradicated in developed and developing countries 
• Oncolytic measles virus exhibit minimal effect on normal cells (selectively 
replicates in cancer cells), (Russell and Peng, 2009) 
Newcastle disease 
virus 
• No pathogenic for humans 
• Genome of approx. 15kbp 
• Replication in tumor cells leads to the expression f viral proteins on the tumor 
cell surface 
• Virus stimulates the synthesis of IFN and TNF 
• Oncolytic activity and fast replication in cancer cells 
Reovirus 
• Non-enveloped double-stranded RNA virus 
• Genome of approx. 24kbp 
• Naturally targeted to tumor cells (replication occurs in cells containing RAS 
mutation), (Mahalingam et al., 2015b, Maitra et al., 2014) 
• Highly prevalent in human population, but not associated with any human 
disease 
 
1.9. Safety considerations and host-adenovirus immune interactions 
1.9.1. Adenovirus induced host immunity 
Oncolytic viruses, e.g., adenoviruses are immunogenic and therefore the immune system 
detects them as pathogens (immunogens). First generations of E1/E3 deleted adeno-vectors 
demonstrated a limitation in potency as OVs in gene therapy due to elevated immune responses 
(Muruve, 2004). Additionally, Ads can exhibit acute inflammation causing a significant limitation 
in gene transfer efficacy, and in the worst case destruction of healthy tissue/organ, and even 
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patient’s death (Raper et al., 2003). Ad promotes the innate immune responses causing 
inflammation of transduced tissues and enhanced clearance of virus (Muruve, 2004). In turn, an 
adaptive immune reaction can lead to production of anti-adenovirus neutralizing antibodies (Sumida 
et al., 2005). 
  
1.9.1.1. Innate Immunity 
Innate immunity is the first line of defense against invading pathogens, including 
adenoviruses. The innate immune responses are mediated through i) different pattern recognition 
receptors (PRRs) in the intracellular and extracellular compartments (cell surface), (Girardin et al., 
2002, Wang et al., 2007), and ii) nucleotide-binding oligomerization domain/leucine-rich repeat 
(NOD-LRR) family of proteins located within the intracellular compartment (Muruve, 2004). The 
best-known family of such PRRs is Toll-like receptors (TLRs). The most important in Ads infection 
is TLR2, which is located on the cell surface, and IL-9, which is presented in endosomes 
(Appledorn et al., 2008). Toll-like receptors counterplay with numerous viral components: viral 
dsRNA (by TLR3), CpG motifs (by TLR9), glycoproteins (by TLR2 and TLR4), ssRNA (by TLR7 
and TLR8), and intercellular viral particles (by TLR3 and TLR9). Infection with adenoviral vectors 
leads also to antiviral response pathways to DNA viruses. Nucleic acid recognition receptors 
(sensors) are grouped into RNA (RIG-I, MDA5, TLR3, TLR7, TLR8) and DNA (TLR9, DAI, 
AIM2), which are further divided into membrane/endosome TLRs or cytosolic. The antiviral 
detection response involves sensor binding to a target ligand or receptor leading to the activation of 
transcription factors (NF-κB, AP1, IRF3, IRF7), (Stein et al., 2012). Virus recognition launches 
adaptor proteins like MyD88 and TRIF (Takeda and Akira, 2015), causing a signal transduction 
through mitogen-activated protein kinases (MAPKs), and activation of NF-κB. Therefore, the 
recognition of pathogen-associated molecular patterns (PAMPs) by innate receptors leads to the 
activation of inflammatory cytokines (e.g., IL-5, IL-6, IL-8, Il-12, TNF-α, RANTES), type I 
interferon and recruitment of leucocytes. These cytokine responses recruit effector leukocytes: 
granulocytes, NK cells, macrophages and secrete more cytokines in order to perform cytosolic 
functions, and boost immune responses (Muruve, 2004), (Figure 10). Within 24 hours post 
infection, immune responses eradicates around 80% of Ads particles (Worgall et al., 1997). 
 
?? ???
 
Figure 10. Brief overview of innate immune responses to Ads. Adenovirus vectors transduce 
many different cell types (e.g. endothelial cells, infects cancer cells). Later on vectors induce 
inflammatory genes like cytokines and chemokines, leading to recruitment and activation of 
effector cells (e.g. DCs, macrophages) to the site of infection. The effector cells play an important 
role in the innate response to adenoviral infection. NK cells and natural killer T cells, via 
interleukin IL-12 and IL-18, secrete interferon γ, crucial for the development of helper T cell type 1 
(Th1) adaptive immune responses. Monocytes/macrophages also secrete antiviral cytokines and 
present antigens for adaptive immunity. Arrows indicate cascade of interactions between different 
immune cells, viral particles and cell types. Modified from (Muruve, 2004). 
 
1.9.1.2. Adaptive Immunity 
 The major agent in establishing adaptive immune responses (humoral and cellular) are viral 
capsid components: hexon (Sumida et al., 2005), penton and fiber (Yu et al., 2013). Innate immune 
responses induce local inflammation and recruitment of effector leukocytes leading to activation of 
adaptive immune system (Muruve, 2004). The activation of the cellular immune responses occurs 
from four to seven days after the adenoviral infection (Muruve, 2004, Liu et al., 2000). DCs are 
attracted to the site of infection and play an important role between the innate and the adaptive 
immune system. When matured after antigen intake DCs can migrate to secondary lymphoid organs 
and present the antigens (viral and tumor antigens) to T cells. T lymphocytes have ability to identify 
peptide antigens presented by class I and class II molecules encoded MHC. In classical antigen-
presentation scenario, MHC class I molecules present intracellular antigens, whereas MHC class II 
molecules present exogenous antigens. DCs have a specialized capacity to process endogenous 
proteins into the MHC class I pathway (cross-presentation). Cross presentation gives the immune 
system an important mechanism for creating anti-viral immunity. In MHC class II-restricted 
responses, DCs capture pathogen antigens and present them to MHC class II-restricted helper T 
cells in the draining lymph nodes. In turn, in MHC class I-restricted responses, DCs uptake antigens 
?????????????
???????????
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that are endogenously synthesized and present the antigen to class I-restricted-cytotoxic T 
lymphocytes. Adenoviral antigens can be taken up by DCs and cross-presented with MHC class I 
molecules to CD8 T cells (Watts et al., 2003). The activation of T cells requires two signals i) 
antigen specific signal recognized in a context of MHC complex by the T cell receptor, and ii) 
additional co-stimulatory molecules (B7 (B7-1, B7-2), (Harris and Ronchese, 1999, Watts et al., 
2003, Smith-Garvin et al., 2009) present on activated DCs, which bind to CD28 molecules on the T 
cell surface. The activated T cells can then migrate to the site of infection, and selectively eradicate 
infected cells. Humoral immune system plays an important role in addition to T cell responses in 
anti-adenoviral immunity. When B cell detects specific antigen via its B cell receptor, and 
activating signal from a helper T cell, it matures, proliferates, and transform into a plasma B cell, 
producing specific antibodies (McHeyzer-Williams and McHeyzer-Williams, 2005). B cells can 
also became a memory cells and together with memory T cells can mediate long-term immunity 
against viral infections (Russell and Peng, 2009). 	
1.9.2. Adverse events 
Adenoviruses are common human pathogens and infect the respiratory and the intestinal 
tract. An infection usually causes symptoms similar to a common cold (sore throat, sneezing, 
headaches, cough, fever), and can lead to keratoconjunctivitis (Jhanji et al., 2015). Normally the 
adenoviral infection appears asymptomatic. However, it remains an important cause of mortality 
after blood and bone marrow transplantation (La Rosa et al., 2001, Soriano and Perales, 2012). 
Oncolytic adenoviruses are widely used in cancer gene therapy (Nayerossadat et al., 2012).  
The risk of serious side effects following adenovirus administration is rare. However, a gene 
therapy by adenoviral vectors has caused major adverse effects and death of some patients 
(Marshall, 1999, Raper et al., 2003).  Jesse Gelsinger, an 18-year-old patient became the first person 
that died because of multi-organ failure after his participation in gene therapy research at the 
University of Pennsylvania. Gelsinger suffered from a metabolic disorder called ornithine 
transcarbamoylase (OTC) deficiency - inability to metabolize ammonia. In 1999, Gelsinger was 
given a corrective OTC gene coded by a first generation replication-defective adenovirus. 
Intraperitoneal administration of high amount of viral particles (1×1011 plaque-forming units 
[pfu]/kg) caused the systemic activation of immune response, leading to a cytokine storm. Within 2 
hours, the patient developed fever and signs of liver dysfunction. Next the patient fell into a coma 
and suffered multi-organ failure (Vorburger, 2002, Raper et al., 2003, Jenks, 2000, Savulescu, 
2001). Gelsinger died 4 days after receiving the adenoviral injection. However, the i.t. 
administration of up to 1×1012 viral particles is learned to be safe for patients. The most common 
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side effects with adenoviral treatment are reported to be light fever, chills, local pain, and diarrhea. 
Even in cases where an adenoviral load was high and targeted in the liver, only one event of 
hepatotoxity and no symptoms of hepatitis were detected (Vorburger, 2002). Also a treatment of 
cancer patient with ICOVIR-7 was well tolerated (2x1010 - 1×1012 VP). All patients experienced 
grade 1 or 2 side effects (fatigue, fever, anemia, chills, abdominal pain). The correlation between 
viral dose and the severity of side effects has not been identified. No grade 4 to 5 side effects were 
observed during the treatment (Nokisalmi et al., 2010). 
In preclinical studies, the adenoviral vector DNA has been found in the liver, skeletal 
muscle, heart, brain, lung, pancreas, and tumor tissue (Volpers and Kochanek, 2004). When viruses 
are administered i.v., most of the viral vectors accumulate in the liver. Liver toxicity was 
highlighted after patient’s death after intra-hepatic administration of adenovirus. Importantly, route 
of virus administration plays a crucial role in virus toxicity and bio-distribution. When virus is 
administered i.v., Kupffer cells (KC) uptake the vector, leading to necrosis of these cells. 
 
1.9.3. Anti-adenovirus drugs 
Adenovirus can lead to acute or lethal infection in immunocompromised persons 
(Echavarria, 2008). Therefore, the development of novel and more efficient antiviral drugs are in 
high demand. Nowadays there are available few anti-virus agents against i) herpes, ii) hepatitis, iii) 
influenza (Razonable, 2011) and iv) HIV viruses (Zhan et al., 2016, Dolgin, 2014). Although 
lacking FDA approval for treatment for adenovirus infection, there are currently two antiviral drugs 
available for use in adenovirus therapy: Cidofovir and Ribavirin (Waye and Sing, 2010). Cidofovir 
is an acyclic nucleoside phosphonate drug with anti-viral properties against DNA viruses (Hoffman 
et al., 2001). Cidofovir inhibits Ad replication. In turn, Ribavirin is more potent drug towards Ad 
infections. Like Cidofovir, Ribavirin is a nucleoside analogue drug but its mode of action is still 
controversial (Waye and Sing, 2010). An example of promising anti-adenovirus drug currently 
being tested in clinical studies is hexadecyloxypropyl Cidofovir (CMX001), a lipid conjugate of 
Cidofovir. It exhibites antiviral activity against double-strand DNA viruses, such as Ad 3, 5, 7, 8 
and 31 (Toth et al., 2008). CMX001 is orally administrated and is designed to cross the intestinal 
wall. It binds to target cell before being cleaved to release Cidofovir for antiviral action. A Phase I 
clinical trial has demonstrated the CMX001 safety profile and bioavailability (NCT00780182). 
Additionally, another study reported higher antiviral efficacy of CMX001 than Cidofovir, 
importantly with less toxicity to treated patients (Lion et al., 2003). The drug was also tested in 
Phase II trials where its efficacy in immunocomprised patients with CMV infection was evaluated  
(NCT00942305). In this study, 13 immunocompromised patients received CMX001. Virologic 
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response (VR) was evaluated as a 99% drop from baseline or undetectable adenovirus DNA in 
patient’s serum. No serious side effects were reported to CMX001 during this study. CMX001 may 
be a promising therapeutic treatment modality for the treatment of severe adenovirus disease in 
immunocompromised patients (Florescu et al., 2012). 
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2. AIMS OF THE STUDY 
 
Oncolytic virotherapy is a promising approach to treat cancer. However, this strategy also 
has disadvantages – mainly insufficient efficacy. This thesis was based on the hypothesis that by 
combining oncolytic adenoviruses with chemotherapeutic drugs and biological agents, we could 
improve anti-cancer efficacy through synergistic interactions against cancer. 
 
• AIM I: To improve anti-cancer efficacy by combining oncolytic adenoviruses with standard 
of care chemotherapy (Manuscript I) 
• AIM II: To improve anti-cancer efficacy by combining oncolytic adenoviruses with 
experimental anti-cancer agent (Manuscript II) 
• AIM III: To perform safety assessment of adenoviral vectors (Manuscript I, III) 
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3. MATERIALS AND METHODS 	
Materials and methods are described in more detail in the original publications. 
 
3.1. Cell lines (I, II) 
Characteristics of the cell lines used in the studies are described in Table 4. 
 
Table 4. Description of the cell lines. 
Cell line Description Provider/Origin Study/Manuscript 
Jl-1 (ACC 596) Human epithelioid mesothelioma DSMZ
1 I 
MSTO-211H (ACC 390) Human mesothelioma DSMZ1 I 
NCI-H226 (H226, CRL-
5826™) Human mesothelioma ATCC
2 I 
HCT-116 (ACC 581) Human colon carcinoma DSMZ1 II 
A549 (CCL-185™) Human lung carcinoma ATCC II 
CCD-112Sk Human skin fibroblasts Provided by Dr Santos3 II 
1Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) 
2American Type Culture Collection (Manassas, VA, USA) 
3Helder A. Santos (Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of 
Helsinki, Helsinki, Finland) 
 
All cell lines were cultured under the conditions recommended by the cell providers. 
 
3.2. Viruses (I-III) 
Characteristics of the viruses used in the studies are described in Table 5. Adenoviruses 
were propagated on A549 cell line and purified on cesium chloride gradients. Viral particle (VP) 
concentration of adenoviruses was assessed by measuring the absorbance at 260 nm. The number of 
infectious units (IU/ml) was assessed by immunocytochemistry assay (ICC) on A549 cells. Virus 
constructs were checked by PCR for the presence of transgenes and genetic modifications (d24, 
GM-CSF, knob modifications). Details on virus engineering are described in the original 
publications or in provided references. 
 
Table 5. Description of the viruses used in the studies. 
Vrus Description Source Study/Manuscript 
Ad5/3-d24-GM-CSF  
(ONCOS-102) 
Human adenovirus, chimera 5/3 (serotype for 
3 knob domain), deletion of 24bp in E1A 
region, coding for human GM-CSF 
Targovax Oy 
(Helsinki, 
Finland) 
I, III 
Ad5-d24-RFP 
Human adenovirus, serotype 5, deletion of 
24bp in E1A region, coding for the red 
fluorescence protein (RFP) 
Provided by 
Dr Suzuki1 II 
Ad5-d24-CpG Human adenovirus, serotype 5, deletion of 24bp in E1A region, coding for the CpG 
IVT, HU 
(Helsinki, 
Finland) 
II 
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Ad5/3luc1 
Human non-replicating serotype 5 adenovirus 
expressing a reporter firefly luciferase 
transgene 
Targovax Oy 
(Helsinki, 
Finland) 
III 
1Dr	Masataka	Suzuki	(Baylor	College	of	Medicine,	TX,	USA)		
3.3. Anti-cancer agents (I - III) 
 
Anti-cancer agents used in the studies are described in Table 6.		
Table 6. Anti-cancer agents used in the studies. 
Name Description Provider Study/Manuscript 
Pemetrexed 
(Pemetrexed 
Disodium) 
Pemetrexed is a chemotherapeutic drug 
that prevents the DNA and RNA 
formation required for the growth and 
survival of both normal cells and cancer 
cells 
Santa Cruz 
Biotechnology, 
Inc., Dallas, TX, 
USA 
I 
Cisplatin 
Cisplatin is a class of platinum anti-
cancer drugs. It crosslinks DNA leading 
to the cell apoptosis 
Santa Cruz 
Biotechnology, 
Inc., Dallas, TX, 
USA 
I 
Carboplatin  
Carboplatin belongs to the class of 
platinum anti-cancer drugs. Interacts 
with DNA causing disruption in cell 
division and mitosis 
Santa Cruz 
Biotechnology, 
Inc., Dallas, TX, 
USA 
I 
Cyclophosphamide 
A chemotherapeutic drug, forms DNA 
crosslinks, leading to cell apoptosis. 
Importantly Cyclophosphamide 
launches beneficial immunomodulatory 
effects in adaptive immunotherapy 
Sigma Aldrich, 
Germany III 
L-Carnosine 
Natural dipeptide (β-alanine and L-
histidine) exhibiting anti-proliferative 
and antioxidant properties. 
Endogenously synthetized in brain, 
kidney, skeletal muscles 
Sigma Aldrich, 
Germany II 
L-Carnosine-6K 
A modified version of L-Carnosine 
featuring 6 additional lysines at the C-
terminus 
Gene Cust Europe 
Laboratoire de 
Biotechnologie du 
Luxembourg S.A, 
Luxembourg 
II 
	
3.4. In vitro studies (I, II) 
Description of in vitro assays, experiments and techniques performed in these studies are 
presented in Table 7.		
Table 7. Description of in vitro studies. 
Assay Description Study/Manuscript 
Cell viability assay 
(MTS) 
Cells were seeded at 1 × 104 cells per well on 96-well plates. 
After overnight incubation the cells were infected with 
ONCOS-102/Ad5-d24-CpG/complex (Ad5-d24-CpG with L-
Carnosine and L-Carnosine-6K) with a viral particles/cell ratio 
I, II 
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of 0,1/1/10/100 (VP/cell). The virus and chemotherapeutic 
agents were diluted in media containing 5% FBS. Pemetrexed, 
Cisplatin and Carboplatin were tested at the following sub-
optimal, previously selected concentrations of 0,625 mg/ml, 
0,0026 mg/ml, 0,0625 mg/ml (H226 cells); 0,625 mg/ml, 
0,0006 mg/ml, 0,0019 6 mg/ml (Jl-1 cells); 0,083 mg/ml, 
0,0026 mg/ml, 0,0625 mg/ml (MSTO-211H cells), 
respectively. Cell viability was determined 1/2/3 days later by 
CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(MTS) according to manufacturer’s instruction (Promega, 
Madison, WI) 
Analysis of 
apoptotic and 
necrotic cell death 
Cells were seeded onto 6 well plates at 2x105/5x105 cells/well. 
Cells were infected with 10 VP/cell of ONCOS-102/Ad5-d24-
GM-CSF/complex (Ad5-d24-CpG with L-Carnosine and L-
Carnosine-6K) and supplemented with chemotherapeutics 
according to the treatment scheme. The amount of apoptotic 
and necrotic cells was measured 24/48 hours later with a 
TACS Annexin V-FITC kit (Trevigen Inc., Gaithersburg, MD) 
according to manufacturer´s instructions by flow cytometer 
(LSR II, BD, Franklin Lakes, NJ) 
I, II 
Immunogenicity of 
tumor cell death  
CRT exposure: Mesothelioma cells were seeded in duplicate 
onto 6 well plates at 5x105 cells/well. Cells were infected with 
10 VP/cell of ONCOS-102 and/or with chemotherapeutic 
agents according to the treatment combinations. 24 (H226, Jl-
1) and 48 (MSTO-211H) hours later cells were harvested and 
stained with 1:1000 diluted rabbit polyclonal anti-Calreticulin 
antibody (Abcam, Cambridge, UK) for 40 min at 4°C and 
subsequently with 1:100 diluted Alexa-Fluor 488 secondary 
antibody (Invitrogen, Carlsbad, CA) and analyzed by flow 
cytometry (LSR II, BD, Franklin Lakes, NJ)  
HMGB-1 release: mesothelioma cells were seeded in triplicate 
onto 96 well plates at 1x104 cells/well and infected with 10 
VP/cell of ONCOS-102 and/or with chemotherapeutic agents 
according to the treatment combinations. 72 hours later, 
supernatants were collected and HMGB-1 was measured with 
an Elisa kit according to manufacturer’s instruction (MBL 
International, Woburn, MA)  
ATP release: mesothelioma cells were seeded in triplicates 
onto 96 well plates at 1x104 cells/well and treated as mentioned 
above. Supernatants were collected after 48 (Jl-1, MSTO-
211H) and 72 (H226) hours and analyzed with ATP 
Determination Kit according to manufacturer’s protocol 
(Promega, Madison, WI) for luminometric analysis (Varioscan 
Flash, ThermoFisher Scientific, Waltham, MA) 
I 
Immunocytochemis
try assay 
Cell lines were seeded in 5 replicates onto 24 well plates at 2x 
x105/3x105 cells/well and treated with different schemes 
according to treatment. 24 hours later, supernatant was 
aspirated and cells were fixed by incubation with ice-cold 
methanol for 15 minutes. The determination of the adenovirus 
infectivity was based on visual quantification of viral hexon 
protein in infected cells. Cells were stained with 1:2000 diluted 
mouse anti-hexon antibody (Novus Biologicals, Littleton, CO) 
for 1 hour at RT in the dark and subsequently with 1:500 
diluted Biotin-SP-conjugated secondary antibody (Jackson 
Immuno Research, West Grove, PA) for 1 hour at RT in the 
I, II 
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dark. Subsequently the Extravidin-peroxidase was added at 
1:200 and incubated for 30 minutes at RT in the dark (Sigma-
Aldrich, Germany). Finally, the infected cells were visualized 
by adding the stain: DAB up to 5 minutes (Sigma-Aldrich, 
Germany). For each 5 replicates (wells) 5 images of non-
overlapping fields was acquired using an AMG EVO XL 
microscope (ThermoFisher Scientific, Waltham, MA). 
Infectivity data is presented as the average number of spots in 
5 wells 
Receptor 
expression studies 
CAR, CD46 and DSG2 expression level in H226, JL-1 and 
MSTO-211H cells was assessed by staining with mouse 
monoclonal anti-CAR antibody (Santa Cruz Biotech, Dallas, 
TX); mouse monoclonal anti-CD46 antibody (Abcam, 
Cambridge, UK) and subsequently with 1:2000 diluted Alexa-
Fluor 488 secondary antibody (Abcam, Cambridge, UK); 
mouse monoclonal anti-DSG2 antibody (Abcam, Cambridge, 
UK) and subsequently with 1:2000 diluted Alexa-Fluor 488 
secondary antibody (Abcam, Cambridge, UK) respectively for 
flow cytometry analysis (LSR II, BD, Franklin Lakes, NJ)  
I 
 
Transduction assay 
Cells were seeded at a density of 1x104 cells/well in 96 well 
plates. On the following day cells were infected using Ad5-
d24-RFP (100 VP, 10 VP, 1 VP, 0,1 VP) and virus-L-
Carnosine complex (100 VP, 10 VP, 1 VP, 0,1 VP). Red 
fluorescence was measured by Varioskan plate reader 
(Varioscan Flash, ThermoFisher Scientific, Waltham, MA) at 
24h, 48h, and 72h after the treatment 
II 
qPCR 
qPCR for adenovirus E4 copy number was carried out (primer 
FW: 5´-GGA GTG CGC CGA GAC AAC-3´, primer RV: 5´-
ACT ACG TCC GGC GTT CCA T-3´, probe E4: 5´-[6FAM] -
TGG CAT GAC ACT ACG ACC AAC ACG ATC T-
[TAMRA] -3´). Total DNA was extracted from tested cells 
using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) according to manufacturer’s protocol. Samples were 
analyzed using LighCycler qPCR machine (LighCycler 480, 
Roche, Basel, Switzerland). Actin serves as a reference mRNA 
Total RNA was extracted from HCT116 and A549 cells by 
using the RNeasy mini  kit (Qiagen, Hilden, Germany) and 
was used to synthesize cDNA. The cDNA was then amplified 
(Bio-Rad Laboratories) using iQTM SYBR Green Supermix 
(Bio-Rad Laboratories, Hercules, CA). Actin served as the 
reference mRNA. The primer sequences were as follows:  
IL-8 forward: 5’-AGACAGCAGAGCACACAAGC-3’  
IL-8 reverse: 5’-ATGGTTCCTTCCGGTGGT-3’   
Actin forward: 5‘-CCTCACCCTGAAGTACCCCA-3’  
actin reverse 5’-TCGTCCCAGTTGGTGACGAT-3’ 
II 
Virus-L-Carnosine 
complex formation, 
Zeta Potential and 
Dynamic light 
scattering analysis 
The virus-L-Carnosine complex was formed by mixing 
oncolytic adenovirus and Carnosine-6K at ratio 1:500 and 
incubated at room temperature for 15 minutes using MilliQ 
H2O at pH 7.4 as buffer. 
Zeta potential analysis was performed using 1x1010 viral 
particles. All the samples were diluted in a volume of 800 ul of 
MilliQ H20 at pH 7.4 and injected with a 1 ml syringe in the 
capillary flow cell to measure the electric surface charge of the 
particles. An equilibration time of 120 seconds was set on the 
software to allow the samples to stabilize at 25°C. Dynamic 
II 
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light scattering analysis was performed with a ZetaSizer Nano, 
Malvern (Westborough, MA) 
Western blot 
analysis 
Total extracts of HCT116 and A549 cell lines were probed 
with antibodies against p62 (2 µg/ml), (mouse monoclonal 
antibody, Abnova), LC-3 rabbit polyclonal antibody (1:100), 
(Cell Signaling Technologies, Inc), heat shock protein 27 
(Hsp27), (1:1000), (Abcam) and β-actin (1:200), (Santa Cruz 
Biotechnology). The signals were detected by using the ECL 
kit (K-12045-D50, Advansta, CA) 
II 
	
3.5. Preclinical in vivo studies (I-III) 
 
Animal protocols were reviewed and approved by the Experimental Animal Committee of 
the University of Helsinki and the Provincial Government of Southern Finland (I, II).  Study III was 
performed in compliance with the OECD Principles of Good Laboratory Practice (GLP) C 
(97)186/Final, Directive 2004/10/EC. All animals were quarantined for at least one week, and their 
health status was monitored daily. Animals were euthanized according to local animal care rules 
and to humane end-point guidelines.  
Description of in vivo experiments and study-related analysis are presented in Table 8.		
Table 8. Description of preclinical in vivo experiments and study-related assays. 
Animal study Description Study/Manuscript 
Human 
mesothelioma 
xenograft model  
The NCI-H226 cells in 50 µl were injected into both flanks 
(6E+06/flank/mouse). Tumors were let to grow 8 days prior to 
the treatments. Viruses were administered on every 6 days. One 
group received ONCOS-102 only, two groups received ONCOS-
102 and chemotherapy (Pemetrexed + Cisplatin or Pemetrexed + 
Carboplatin) simultaneously, while two other groups received 
ONCOS-102 priming followed by combinatorial treatment of 
chemotherapy (Pemetrexed + Cisplatin or Pemetrexed + 
Carboplatin) and ONCOS-102 in 3-day cycles. Mock animals 
were treated with 0,9% saline. ONCOS-102 was diluted into 
0,9% saline and injected intratumorally at a dose of 5x107 VP 
per tumor (two tumors per animal). Injections were given in a 
fan-like pattern to ensure even distribution throughout the tumor. 
Pemetrexed, Cisplatin, and Carboplatin were diluted in 0,9% 
NaCl and administrated intraperitoneally at doses of 10 mg/kg, 
1,5 mg/kg, and 8 mg/kg, respectively. The injection volume was 
100µl per chemotherapeutic agent 
I 
Human GM-CSF 
ELISA 
Protein extracts and previously collected serum were analyzed 
for human GM-CSF concentration using ELISA (Abcam, 
Cambridge, UK) according manufacturer’s instructions 
I 
qPCR 
qPCR for adenovirus E4 copy number was carried out (primer 
FW: 5´-GGA GTG CGC CGA GAC AAC-3´, primer RV: 5´-
ACT ACG TCC GGC GTT CCA T-3´, probe E4: 5´-[6FAM] -
TGG CAT GAC ACT ACG ACC AAC ACG ATC T-
[TAMRA] -3´). Total DNA was extracted from BALB/c nude 
I 
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murine samples (tumors, livers, blood) using the QIAamp DNA 
Blood Mini Kit (Qiagen, Hilden, Germany) according to 
manufacturer’s protocol. Subsequently isolated DNA was 
analyzed for adenoviral E4 copy number normalized to murine 
beta-actin (liver, blood) and human beta-actin (tumor), 
respectively ((primer FW: 5´-CGA GCG GTT CCG ATG C-3´, 
primer RV: 5´-TGG ATG CCA CAG GAT TCC AT-3´, probe 
murine beta-actin: 5´-[6FAM)-AGG CTC TTT TCC AGC CTT 
CCT TCT TGG-(TAMRA)-3´; (primer FW: 5´-CAG CAG ATG 
TGG ATC AGC AAG-3´, primer RV: 5´-CTA GAA GCA TTT 
GCG GTG GAC-3´, probe human beta-actin: 5´-[6FAM)- AGG 
AGT ATG ACG CCG GCC CCT C-(TAMRA)-3´). Samples 
were analyzed using LighCycler qPCR machine (LighCycler 
480, Roche, Basel, Switzerland) 
Human xenograft 
model of lung 
cancer 
The oncolytic activity of the Ad5-d24-CpG and virus-L-
Carnosine complex was tested in a lung cancer xenograft model. 
Nude mice bearing A549 cell tumors in the flanks (1x106 
cells/flank injected subcutaneously) were treated intratumorally 
with 1x108 VP/tumor (or PBS) on days 0, 2, 5 and the tumor 
growth was followed over time 
II 
Human colon 
cancer xenograft 
model 
The oncolytic activity of the Ad5-d24-CpG and virus-L-
Carnosine complex was tested in a colon cancer xenograft 
model. Nude mice bearing HCT-116 cell tumors in the flanks 
(1x106 cells/flank injected subcutaneously) were treated 
intratumorally with 1x108 VP/tumor (or PBS) on days 0, 2, 5 and 
the tumor growth was followed over time 
II 
Western blot 
analysis 
Total extracts of HCT116 and A549 cell lines were probed with 
antibodies against Hsp27 (1:1000), (Abcam, Cambridge, UK) 
and β-actin (1:200), (Santa Cruz Biotechnology, Dallas, TX, 
USA). The signals were detected by using the ECL kit (K, 
Advansta, CA) 
II 
Toxicity and bio-
distribution 
studies – Syrian 
hamsters 
The study was carried out with 300 hamsters (Syrian hamsters), 
divided into nine test groups – three groups for bio-distribution 
and six groups for toxicity analysis. Animals were sorted 
according to the body weight, and allocated to the dose group. 
Hamsters received ONCOS-102 in NaCl solution by intracardial, 
intraperitoneal or subcutaneous injections. Additionally, one 
group was administered with intraperitoneal injections of 
Cyclophosphamide in dose of 20 mg/kg. The control animals 
were administered with NaCl solution without ONCOS-102 in 
the same volume and way.  
III 
Hematology and 
clinical chemistry 
Blood samples for hematology (Manuscript III, Table S1) and 
clinical chemistry (Manuscript III, Table S2) were collected on 
scheduled time. The animals were fasted for approximately 12-
18 hours before blood sampling, but water was provided ad 
libitum. Blood samples were drawn under ether anesthesia from 
the retro-orbital venous plexus into tubes containing K3-EDTA 
(hematology), sodium citrate (for coagulation), and into 
TAPVAL (without anti-coagulant for serum clinical chemistry). 
Blood samples for coagulation, serum chemistry and analysis of 
antibodies were centrifuged (4000 rpm for 15 min and 6000 rpm 
for 10 min, respectively) and serum was transferred into plastic 
tubes 
III 
 
 
Whole organs or samples of the collected tissues were preserved 
in 4% neutral buffered formaldehyde. The eyes, optic nerves, 
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Necropsy 
testes and epididymitis were fixed in Davidson's fluid and then 
moved to 4% neutral buffered formaldehyde. Histopathology 
was performed on days 29, 190 and 256 for selected organs and 
tissues. Histopathological examination was performed. Tissues 
from all animals were wax embedded, cut at a nominal thickness 
of approximately 5µm, stained with haematoxylin and eosin 
(HE) and examined microscopically 
 
 
III 
Neutralization 
antibody assay 
Ad5/3luc1, a non-replicating serotype 5 adenovirus expressing a 
reporter firefly luciferase transgene, was used to indirectly 
quantify blocking activity of the serum on virus infectivity of 
permissive cells in culture. Known concentrations of rabbit anti-
Ad5/3 NAbs were used to quantify the assay 
III 
qPCR 
The number of adenoviral copies (E1 region) and hamster Gapdh 
sequence were determined in DNA samples. Samples of feces 
were isolated using NucleoSpin kit, samples of urine and buccal 
swabs were isolated using NucleoSpin Blood DNA isolation, 
and serum samples were isolated using NucleoSpin Blood DNA 
isolation kit according to the manufacturer´s instructions 
(Macherey-Nagel, Bethlehem, PA). In tissue samples the 
concentration of adenoviral sequence (primer FWE1: 5´-TCC 
GGT TTC TAT GCC AAA CCT-3´, primer RVE1: 5´- TCC 
TCC GGT GAT AAT GAC AAG A-3´, probe adenoE1: 5- ATC 
GAT CCA CCC AGT GAC GAC-3) was normalized by the 
concentration of hamster’s Gapdh sequence (primer FWGapdh: 
5´- CAC CGA GGA CCA GGT TGTC T-3´, primer RVGapdh: 
5´-CAT ACC AGG AGA TGA GCT TTA CGA-3´, probe 
Gapdh: 5-CAA TGC CAG CCC CAG CATC A-3) or by the 
total amount of DNA 
III 
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4. RESULTS  
This chapter summarizes the main results of the thesis. More details can be found in the 
original publications (I-III). 
The scope of this thesis was to: 1) improve efficacy of oncolytic adenovirus in cancer 
therapy by combining it with other treatment modalities: i) chemotherapy (I) and ii) experimental 
biological agent (II). The second objective 2) was to perform a viral safety assessment (I, III), 
(Figure 12). 
?
Figure 12. Brief overview of the studies carried out and presented in this thesis. Manuscript I 
describes synergistic anti-cancer efficacy in vitro and in vivo by combining ONCOS-102 with 
standard of care chemotherapy (Pemetrexed+Cisplatin or Pemetrexed+Carboplatin). Manuscript II 
presents enhanced anti-cancer efficacy in vitro and in vivo by combining oncolytic adenovirus with 
L-Carnosine in colon and lung cancer model (II). Manuscript III describes safety assessment of 
adenovirus vectors in Syrian hamsters and nude BALB/c mice (toxicology, biodistribution, Nabs, 
GM-CSF production). 
 
4.1. Improved anti-cancer efficacy by combining oncolytic adenoviruses with standard of care 
chemotherapy (I) 
Combinatory studies with oncolytic adenovirus and chemotherapeutic agents in 
mesothelioma therapy were carried out both in vitro and in vivo. Oncolytic properties of ONCOS-
102 were tested in three mesothelioma cell lines in vitro (Fig. 3A, I). JL-1, MSTO-211H and H226 
cells appeared to be relatively resistant to oncolysis as 10 VP/cell killed 18%, 24% and 11% of 
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cells, respectively, in 3 days. JL-1 and H226 cell lines were more resistant to chemotherapy-
mediated cytotoxicity compared to MSTO-211H cells (Pemetrexed + Cisplatin or Pemetrexed + 
Carboplatin). Incubation with chemotherapeutics killed only 10% of JL-1 and 11-12% of H226 
cells in 3 days.  In contrast, 63% and 73% of MSTO-211H cells were killed by day 3 in culture with 
Pemetrexed + Cisplatin or Pemetrexed + Carboplatin, respectively. Compared to the results 
observed in the single-treatment (virus alone and chemotherapy alone), the combination of 
ONCOS-102 with chemotherapeutics significantly increased cytotoxicity in H226 (p<0.05) and JL-
1 (p<0.001) cells (Fig. 1A, I). 
In line with the cell viability results, the number of apoptotic H226 and JL-1 cells was 
generally low in all treatment groups, but a combination treatment slightly increased the number of 
apoptotic cells in comparison to monotherapies (Figure 1 B and 1 C, I). 
Markers for immunogenic cell death, such as the exposure of calreticulin to cell surface and 
the extracellular release of ATP and HMGB1, were measured from mesotheolioma cell cultures 
after exposure to ONCOS-102, chemotherapeutic agents, or combination of both. The most 
immunogenic tumor cell death (the highest number of extracellular HMGB1, ATP and CRT 
positive cells) was triggered by treatment with ONCOS-102 + chemotherapy (Pemetrexed + 
Cisplatin or Pemetrexed + Carboplatin) in H226, JL-1 and MSTO-211H cells (Fig. 2, I).  
In order to study the synergy of oncolytic virus and chemotherapeutics on anti-tumor 
treatment, we performed animal studies. Subcutaneous human mesothelioma H226 tumors were 
treated according to the treatment regime presented in Table 1 (I). Tumors appeared to be refractory 
against standard chemotherapeutics (Pemetrexed + Cisplatin, Pemetrexed + Carboplatin), as none 
of the treatments significantly reduced tumor growth (Figure 4A, I). Chemotherapy alone was the 
most inefficient treatment modality against mesothelioma. One animal treated with ONCOS-102 + 
Pemetrexed + Cisplatin showed a complete tumor regression (both tumors) by day 21. In addition, 
one animal treated with ONCOS-102 priming + Pemetrexed + Cisplatin showed a complete 
regression of both tumors by day 45. Indeed, this regimen was the most effective with 97% of initial 
tumor size at day 60 vs. 473% (mock), 563% (Pemetrexed + Cisplatin) and 672% (Pemetrexed and 
Carboplatin). Additionally, in all combination regimes (ONCOS-102 + chemotherapy) we observed 
the most significant anti-tumor activity compared to other groups (e.g. initial tumor size: 97% [virus 
priming + Pemetrexed + Cisplatin], 138% [virus + Pemetrexed + Cispaltin] vs. 206% [virus alone], 
473% [mock], 563% [Pemetrexed + Cisplatin] at day 60), (Fig. 4A, I). Importantly, ONCOS-102 
combined with chemotherapeutics showed a strong synergistic anti-tumor effect (R>1) on day 21, 
48 and 60 (Table 2, I). 
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4.2. Improved anti-cancer efficacy by combining oncolytic adenoviruses with experimental 
anti-cancer agent (II) 
Anti-cancer properties of Carnosine-6K complexed with oncolytic adenovirus was tested in 
vitro and in vivo in: i) colon and ii) lung cancer models. 
We showed that Carnosine-6K coated viruses (complex) displayed increased transduction 
efficacy and enhanced infectious titer over virus and Carnosine-6K alone in colon and lung cancer 
cells in vitro (Figure 2, II). Additionally, Carnosine-6K coated adenovirus induced the strongest 
apoptotic/necrotic cell death in tested cell lines (Figure 4, II). We found that virus-L-Carnosine 
complex exhibited the most potent anti-cancer properties by enhancing viral replication, inducing 
autophagy and affecting the expression of Hsp27. In HCT116 cells, Carnosine-6K loaded 
Ad5D24CpG improved antitumor efficacy by enhancing the viral replication and inducing 
autophagy. In turn, in A549 cells the complex exhibited the most potent anti-cancer effect through 
down-regulation of Hsp27, leading to lower expression of IL-8 (Figure 5-6, II).  
The oncolytic activity of the virus-L-Carnosine complex was also tested in a lung and colon 
cancer xenograft models. Nude mice bearing A549 and HCT-116 cell tumors in the flanks were 
treated intratumorally with 1x108 VP/tumor (or PBS) on days 0, 2, 5 and the tumor grow was 
followed over time. We observed that the tumor growth was significantly (p <0.001 at day 18) 
reduced in virus-L-Carnosine complex treated mice compared to the control virus or Carnosine-6K 
alone (Figure 7 A, 7 B, II). We then calculated the therapeutic synergy between Ad5D24CpG and 
Carnosine-6K using Fractional tumor volume (FTV) method. We found synergistic effects in A549 
mouse treated with complex compared to mice treated with mix (virus and L-Carnosine 
administered separately). In HCT-116, we found a synergistic effect in both virus-L-Carnosine 
complex and mix condition, however, the effect was stronger in mice treated with the complex 
(Figure 7 C, 7 D and Supplementary Table 1, II). Recent studies underline that the Hsp27 
expression strongly correlates with poor survival in patients with rectal cancer (Vidyasagar et al., 
2012, Tweedle et al., 2010). For this reason we evaluated the expression of Hsp27 in protein 
extracts obtained from xenograft tumors. Surprisingly, we found that the expression of Hsp27 was 
dramatically reduced in both xenograft tumors after intratumoral administration of the virus-L-
Carnosine complex. (Figure 7 E, 7 F, II).  	
4.3. Safety assessment of adenoviral vectors (I, III) 
Safety assessment was done in different preclinical setups: i) GLP toxicological and 
biodistribution study before the human clinical trial (III), and ii) as part of the combination study of 
ONCOS-102 with SoC chemotherapy in a mesothelioma model (I). 
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The study (III) was carried out in 300 hamsters divided into nine test groups – three bio-
distribution groups and six groups for analysis of toxicity. Hamsters received the tested dose of 
ONCOS-102 in NaCl solution by intracardial, intraperitoneal or subcutaneous injections (Table 1, 
III). Additionally, one group was administered twice a week with intraperitoneal injections of 
Cyclophosphamide in dose of 20 mg/kg. The control animals were administered with NaCl solution 
without ONCOS-102 in the same volume and way. No adverse effects were observed of repeated 
administration of ONCOS-102 on clinical signs including body weight (Figure 1-2, III), food 
consumption (Figure 3, III), hematology and clinical chemistry parameters (Table S4 and S5, III), 
histopathology (Table 2, III) and bio-accumulation (Figure 4-7, III) in the course of 6-month 
administration and following 3- month recovery period.  
In study (I), the weight of the nude mice was followed throughout the experiment (Figure S1 
B, Figure S2 B, Figure S3, I). A minor weight loss was observed in the following groups: 
Pemetrexed + Cisplatin (10% of decrease at day 48, 11% at day 60), ONCOS-102 priming 
Pemetrexed + Cisplatin (9% of decrease at day 48, 12% at day 60), Pemetrexed + Carboplatin (6% 
at day 60), (Figure S3, I).  
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5. DISCUSSION 
5.1. Improved anti-cancer efficacy by combining oncolytic adenoviruses with other 
therapeutic agents 
 
Improved anti-cancer efficacy by combining oncolytic adenoviruses with standard of care 
chemotherapy 
The thesis shows that ONCOS-102 in combination with SoC chemotherapy mediates ICD in 
a preclinical setting. Combination increased immunogenic cell killing in vitro, further suggesting 
that the virus-induced ICD plays a part in the antitumor T-cell activation observed in humans 
treated with ONCOS-102 (Vassilev et al., 2015, Ranki et al., 2014a, Ranki et al., 2016). The 
molecular mechanisms underlying this phenomenon are still unknown, several hypotheses can 
however, be suggested. The production of adenovirus E1A proteins has been shown to sensitize 
cancer cells to chemotherapy-induced cell killing. Chemotherapeutics have also been shown to 
induce immunogenic cell death resulting in induction of anti-cancer immunity and anti-cancer 
efficacy (Liikanen et al., 2013), which is in line with our observations, where calreticulin exposure 
and release of ATP and HMGB1 were highest when treating with the ONCOS-102 combined with 
SoC chemotherapy.  
The data also show that combinatory therapy results in synergistic anti-cancer effects and is 
the most effective treatment regime against mesothelioma tested in this setting. The findings are in 
line with reported results where ONCOS-102 combined with doxorubicin exhibited a synergized 
antitumor effect against soft STS in Syrian hamsters (Siurala et al., 2015). Similar results have been 
shown by combining Ad5/3-delta24 with gemcitabine, resulting in synergistic effects against 
ovarian cancer in vitro and in vivo (Raki et al., 2005).  
In numerous preclinical studies, the combination of Pemetrexed with Cisplatin has shown 
activity against human non-small cell lung cancer cells, suggesting potential efficacy in 
mesothelioma (Vogelzang et al., 2003, Rusch, 2003). In the Phase III trial conducted by Vogelzang 
et al, an improved overall survival was seen when patients were treated with the chemotherapeutics 
combination versus single drugs. Despite the improved efficacy by the chemotherapeutic 
combination, MM is still a lethal disease (Belli et al., 2009). The combination of oncolytic viruses 
with chemotherapeutic drugs has a potential for enhanced anti-cancer killing efficacy and induction 
of anti-cancer immunity. Combining ONCOS-102 with chemotherapy can overcome the major 
obstacle of immune suppressive microenvironment in tumors (Diaconu et al., 2012) due to the 
immunogenic tumor cell death (Kepp et al., 2011, Wong et al., 2015, Siurala et al., 2015, Kroemer 
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et al., 2013) and subsequent mediation of anti-cancer immune responses (Gilboa, 1999, Liikanen et 
al., 2013, Kepp et al., 2011).  
Thesis results provide a strong rationale to test the combination of ONCOS-102 and 
Pemetrexed with Cisplatin/Carboplatin in clinical settings. This strategy could be a potential future 
treatment option for mesothelioma patients. Study of other chemotherapy combinations could also 
be beneficial.    
 
Improved anti-cancer efficacy by combining oncolytic adenoviruses with experimental anti-cancer 
agent  
In the second study, we found that the complex formed by the interaction between 
Carnosine-6K and adenovirus is able to induce apoptosis and necrosis in vitro at significantly lower 
concentrations of Carnosine-6K. Interestingly, the complex exhibited the most potent anti-cancer 
effect compared to other tested modalities, perhaps because Carnosine-6K used the virus as a carrier 
to maximize cell entry. This hypothesis was suggested by in vitro cell viability assay, where the 
virus L-Carnosine complex had the highest infectivity titer and transduction rate compared to other 
gest groups. 
It has been reported that the intraduodenal administration of L-Carnosine inhibits the 
proliferation of HCT116 cells in BALB/c nude mice. In vivo data revealed that 1mg/ml of L-
Carnosine solution given in the drinking water from 6 to 22 days inhibited tumor growth (Horii et 
al., 2012). Our studies show that intratumoral administration of the virus-L-Carnosine complex 
results in significant synergistic suppression of tumor growth compared to other test groups. Most 
of the tumors were fully eradicated within 18 days after injection. We also found that the expression 
of Hsp27 dramatically reduced after the treatment with the virus-L-Carnosine complex formulation 
in both xenograft tumors. This is a promising result as recent studies suggest Hsp27 as a molecular 
target for inhibition in cancer therapy (Kim and Kim, 2011). The observed synergistic anti-cancer 
effects with the virus-L-Carnosine complex were based on enhanced autophagy, and on expression 
of Hsp27. Indeed, it has been reported that adenovirus induces cell lysis through autophagy in order 
to use autophagy-related vacuoles for the egress (Jiang et al., 2011). LC3I to LC3II conversion 
observed in HCT116 and in A549 cells has shown that the complex increases autophagy, which 
strongly promotes virus replication in colon cancer cells (Rodriguez-Rocha et al., 2011, Cheng et 
al., 2013). In agreement with these results, we found that in the HCT116 cell line, a significant 
increase of viral particles was detected by qPCR after complex infection.  
The heat shock protein expression seems to play a crucial role not only in tumor cell 
survival and proliferation but also in viral replication and in mediating the viral infection signaling 
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(Glotzer et al., 2000). Few studies support the idea that cells with higher HSPs expression might 
have more favorable environment for virus replication (Wang et al., 2010). HSP overexpression 
may change the expression level of certain genes, including those responsible for adenovirus life 
cycle in cells, such as CAR, which affects the infection and replication of adenovirus. It is known 
that HCT116 cells express high level of Hsp27 (Hayashi et al., 2012). Indeed, we found that Hsp27 
levels were higher in HCT116 compared to A549 cell line. The high basal expression of Hsp27 
might favour the environment for virus replication and also exert anti-apoptotic function, helping 
the virus to form new virus particles in an early phase of virus-L-Carnosine complex infection. 
These results are in agreement with the hypothesis that HSPs expression enhances the oncolytic 
effect of replicative adenovirus (Wang et al., 2010).   
Since it is known that in lung tumor cells Hsp27 expression is correlated with cancer cell 
resistance against apoptosis (Lelj-Garolla et al., 2015), we hypothesized that the replication of the 
virus-L-Carnosine complex in A549 cells can lead to reduction of Hsp27 levels. Down-regulation 
of Hsp27 is able to reduce IL-8 expression (Rajaiya et al., 2012). Endogenous expression of IL-8 
has been found in various human cancers, including colon and lung cancers. Evidence shows that 
IL-8 biological activity may contribute to cancer progression, and in other circumstances induce an 
anti-tumor response. In our studies, a significant decrease of IL-8 mRNA take place only in A549 
cells, which over-expresses EGFR. As IL-8 is involved in tumor cell proliferation via EGFR, the 
IL-8 decrease might explain the better antitumor effect of the complex (Shi et al., 2014, Diaz et al., 
2010). 
This therapy could be a potential future treatment of lung and colon cancer. Additionally, 
this virus-platform can be used in future studies for delivery of other bioactive drugs, and 
antibodies, as well as a novel strategy in cancer therapy. 
 
5.2. Safety assessment of adenoviral vectors 
Treatment with ONCOS-102 did not cause any major adverse effects on body weight, food 
consumption, hematology and clinical chemistry parameters in tested groups compared to control 
animals during and after the treatment period. These results are in line with extensive clinical and 
non-clinical evidence demonstrating the good safety profile of adenoviruses. Hundreds of cancer 
patients have been treated with replication competent serotype 5 adenovirus, Onyx-015, in 
numerous clinical trials (Nemunaitis et al., 2001, Kirn, 2001a). Onyx-015 was generally well 
tolerated at doses of up to 2×1012 viral particles by intratumoral, intraperitoneal, hepatic arterial and 
intravenous administration. No DLTs were identified by any route of administration. Flu-like 
symptoms have been the most typical toxicities (Kirn, 2001a). Similar findings with no DLTs have 
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been reported in a Phase I study of 18 melanoma patients receiving combination therapy with T-
VEC and anti-CTLA-4 antibody (Turnbull et al., 2015). No dose-limiting toxicity or MTD has been 
noticed as well in Phase I clinical trial of intratumoral infusion of reovirus for the treatment of 
recurrent malignant gliomas (Kicielinski et al., 2014). Thousands of patients have also been treated 
in numerous trials testing adenovirus and importantly all studies were without any major virus-
related complications, and the assessment of DLT and MTD has not been identified in any of the 
trials (Wollmann et al., 2012). The safety of adenoviral cancer gene therapy has been very well 
studied and concluded as a patient-safe therapy (Koski et al., 2009, Freytag et al., 2007, Lubaroff et 
al., 2009). Our obtained findings agree with the previous studies that adenovirus administration is 
safe.  
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6. SUMMARY  
We tested various treatment combinations with the overall goal being improvement of 
efficacy of oncolytic virotherapy (I, II) and safety studies of adenoviral vectors (I, III). With the 
first goal in mind, we studied two setups: i) oncolytic adenovirus + SoC chemotherapies and, ii) 
oncolytic adenovirus complexed with L-Carnosine.  
In study (I) we tested the anti-cancer activity of combination treatment with SoC 
chemotherapy (Pemetrexed, Cisplatin, Carboplatin) and ONCOS-102 in xenograft BALB/c model 
of human MM. We showed that oncolytic adenovirus is able to induce ICD of human mesothelioma 
cell lines in vitro and anti-tumor activity in H226 MPM xenograft model. Chemotherapy alone 
showed no anti-tumor activity in the mesothelioma model. However, a synergistic anti-tumor effect 
was seen when ONCOS-102 was combined with chemotherapy regimens.   
In study (II) we have tested anti-cancer properties of the biological drug L-Carnosine 
complexed with oncolytic adenovirus. The virus-L-Carnosine complex demonstrated improved 
anti-tumor efficacy in vitro and in vivo. In HCT116 colon and A549 lung cancer cells the complex 
presented a higher transduction level and infectious titer over uncoated oncolytic adenovirus. The in 
vivo efficacy of the complex was tested in lung and colon cancer xenograft models, in which it 
exhibited a significant reduction in tumor growth over virus and L-Carnosine alone. Additionally, 
we investigated the molecular mechanisms underlying the efficacy of virus-L-Carnosine complex 
and found that it induced apoptosis in both cells lines by enhancing viral replication and affecting 
the expression of Hsp27.  
The second aim of the thesis was to perform a safety assessment of adenovirus vector in i) 
GLP toxicological and bio-distribution study of repeated administration of ONCOS-102 in hamsters 
(III), ii) and as part of the combination therapy study of ONCOS-102 with SoC chemotherapy in a 
mesothelioma model (I). The study (III) was carried out in 300 hamsters organized into nine test 
groups – three bio-distribution groups and six groups for analysis of toxicity. Repeated 
administration of ONCOS-102 showed no side effects on clinical signs including body weight, food 
consumption, hematology, clinical chemistry parameters, histopathology and bio-accumulation in 
the course of 6-month administration and following 3-month recovery period. Study (I) did not 
show any major adverse effects of combined administration of ONCOS-102 with SoC 
chemotherapy on clinical signs, such as body weight and bio-distribution, in the 2-months 
administration period in tested mice.  
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7. CONCLUSIONS  
Study results show synergism in vitro and in vivo and provide a strong rationale to test the 
combination of ONCOS-102 and Pemetrexed with Cisplatin/Carboplatin in clinical settings. This 
treatment strategy could be a potential future treatment for mesothelioma patients. Additionally, 
tested combinations of ONCOS-102 and SoC chemotherapy seem to be a very promising setups for 
clinical development, supporting the study of other chemotherapy combinations with the virus in 
different cancer types (I).  
The virus-L-Carnosine complex demonstrated significant anti-tumor efficacy both in vitro 
and in vivo compared to the virus or Carnosine-6K alone in colon and lung cancer models. This 
strategy could be a potential future treatment of lung and colon cancer. Additionally, this virus-
platform can be used in future studies for delivery of other bioactive drugs, antibodies, and as novel 
strategy in cancer therapy (II). 
All obtained findings indicate that studied adenoviral vectors and combination therapies are 
safe. Thus, it is possible to use these treatment strategies in clinical settings, without added safety 
concerns (I, III).  
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8. FUTURE PROSPECS 
We are entering an exciting stage in the development of onco-immunotherapy. The 
discovery of checkpoint inhibitors such as anti- CTLA-4, PD-1 and PD-L1 resulted in tremendous 
tumor regression in cancer patients. However, it has been well reported that the blockade of 
immune checkpoints alone is seldom curative (Ai and Curran, 2015), but it has the capacity to 
synergize with other approaches to activate anti-cancer immune responses (Vile, 2014). One of the 
most exciting and scientifically well-justified combination could be oncolytic viral therapy with 
checkpoint inhibitors. Indeed, a few clinical trials combining the oncolytic HSV T-VEC with anti 
CTL-4 anti PD-1 have been proposed, however, no results have been published yet.  
Oncolytic virus immunotherapy is also entering an exciting phase of their application, the 
FDA and EMA have recently approved T-VEC. The safety and anti-cancer efficacy of T-VEC as a 
monotherapy has been shown in many clinical trials (Kaufman et al., 2016, Ott and Hodi, 2016). 
Combination therapies, utilizing conventional and novel therapies, will be the future promise of 
cancer treatment. It has already been reported that oncolytic viruses have the potential to present 
additive or even synergistic effects with various treatment modalities (radiotherapy, chemotherapy, 
biological drugs), (Siurala et al., 2015, Li et al., 2007, Dilley et al., 2005). Importantly, localized 
oncolytic virotherapy can overcome tumor resistance to immune checkpoint blockade therapy and 
enhances anti-cancer immune responses (Zamarin et al., 2014). Numerous candidates of new 
immune checkpoint inhibitors are currently under clinical development targeting molecules other 
than CTLA-4 (Wolchok and Saenger, 2008) or PD-L1/PD-1 (Mahoney et al., 2015, Ott et al., 2013, 
Nghiem et al., 2016). It would be very interesting to check if synergy could be established with 
antibodies targeting LAG-3 or TIM-3 with oncolytic adenoviruses. Additionally, triple combinatory 
studies with oncolytic adenoviruses, chemotherapy and checkpoint inhibitors should be studied as 
well. Finally, currently tested treatment options in cancer therapies are shifting to tailored 
personalized medicine. However, there is lack of specific biomarkers indicating the proper 
therapeutic response in many cancer types, giving a window for the discovery of unmet needs. 		
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